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Abstract 
     Conformational changes of the α-synuclein protein during docking into a phospholipid 
membrane is suspected to play a central role in neuronal cell death during Parkinson’s disease. 
This intrinsically disordered protein obtains its secondary helical structure through a pathway of 
transition states. These states, when improperly folded, are prone to stack into hydrophobic β-
sheets, which later lead to the formation of fibrils and Lewy bodies – the hallmarks of Parkinson’s. 
The ability to elucidate key transition intermediates of α-synuclein will clarify the mechanism 
used in the development of this disease and help facilitate the screening of drugs for the 
treatment of all α-synucleinopathies. In this research, Time-Resolved Hydrogen/Deuterium 
Exchange Mass Spectrometry coupled with the nanodiscs technology as artificial membrane was 
employed to unravel structural behaviour of this protein in the presence of phospholipid bilayer. 
As a result, the conformational behaviour of αSN indicated rather a transient interaction with 
phospholipid bilayer than binding to the nanodisc. The key regions of the most structural 
rearrangements during the interaction with the lipid membrane were identified and were 
consistent with the published literature. Based on the results of the kinetic HDX studies, the data 
proposed an evidence for the structural intermediate of αSN which was proposed in different 
theories on αSN’s conformational behaviour in vivo. 
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Chapter 1: Introduction 
1.1. Hydrogen/Deuterium Mass Spectrometry (HDX-MS) – a Powerful Tool for 
Studying Conformational Dynamics of Proteins 
     1.1.1. Mass Spectrometry 
     Mass spectrometry (MS) is an analytical technique that ionizes molecules and measures these 
ions according to their specific mass-to-charge ratio (m/z) 1,2. The history of MS started with the 
construction of the very first mass spectrometer termed “parabola spectrograph”. In 1907 it was 
built by the Nobel Prize winner - J.J. Thomson on the basis of W. Wien studies on deflecting 
channel rays in a magnetic field 3,4. In 1913, Thomson reported the first successful mass 
spectrometry result, a photographic plate with separate impact marks for the two isotopes Ne20 
and Ne22 4,5. This marked the start of mass spectrometry as a scientific field! Up until the late 
1980’s, MS was mainly used for analysing low molecular weight molecules as no other method 
existed at the time for putting larger molecules (like biomolecules and their complexes) in the 
gas phase. In 1988 and 1989, K. Tanaka and J. B. Fenn were able to circumvent the problem of 
placing intact macromolecules in the gas phase and produce the two main Nobel Prize winning 
soft ionization techniques of today – Matrix Assisted Laser Desorption/Ionization (MALDI) and 
Electrospray Ionization (ESI), respectively 6–9. Soft ionization techniques coupled with more and 
more advanced mass spectrometers was the start to a new direction in MS research - powerful 
analytical methods in life sciences and medicine. One of these young analytical techniques which 
emerged into the world of biochemistry 20 years ago was Hydrogen/Deuterium exchange (HDX) 
Mass Spectrometry. 
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     1.1.2. Hydrogen Deuterium Exchange 
     HDX is a chemical reaction involving the substitution of a covalently bound labile hydrogen 
atom with deuterium 10. The origins of HDX as a bioanalytical approach can be traced to the work 
of Linderstrøm-Lang and colleagues at the Carlsberg laboratories in 1950s, which focussed on 
HDX at the amide backbone of peptides/proteins 11,12. Initially, the goal of their studies was 
measuring stability of hydrogen bonds involved in the formation of secondary protein structures 
using HDX 12–20. Later, they recognized that exchange in the amide backbone of the protein 
relates to conformational changes, which was the first study of protein dynamics using this 
method 11,12,21,22. Hence, the ‘central dogma’ of HDX was born –exchange at the amide backbone 
(hydrogens are shown in teal in Figure 1) of a protein reflects its conformational dynamics, which 
correlates to its fundamental properties and ultimately to biological function 12,23–31. 
Figure 1. Different hydrogen types in the sample peptide His-Leu-Ser-Cys-Lys-Asp. The 
exchangeable backbone amide hydrogens are depicted in teal, and the labile side-chain protons 
are depicted in salmon-pink color. Carbon-bound unexchangeable hydrogens are not indicated.  
 
     Interestingly, HDX was primarily monitored by Nuclear Magnetic Resonance (NMR) until mass 
spectrometers were coupled with ESI and MALDI, but the rapid rise of HDX-MS related 
publications over the last 20 years is a testament to it’s broad applicability in biochemistry, and 
its complementarity to the classical tools of structural biology 12,23–26,32. Compared to HDX-NMR, 
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HDX-MS has the advantage of having virtually no size limitation and can require substantially less 
protein material, but it typically does not provide atomic-level resolution 27,33,34. Modern HDX-
MS combined with new separation and advanced MS technologies, such as ultra-high resolution 
mass separation, ion mobility spectrometry (IMS) and non-ergodic fragmentation, has become 
an essential tool in the investigation of protein-protein, protein-membrane, protein-small 
molecule interactions, as well as drug development, epitope mapping and bio-therapeutics 35–40. 
 
     1.1.2.1 HDX Fundamentals 
     HDX in a protein can occur at any site containing a labile hydrogen (-OH, -SH, -NH), but the 
amide hydrogens on the peptide backbone are by far the most commonly monitored in HDX 
experiments (Figure 1) 20–22,30,41,42.  These hydrogens are uniformly distributed along the 
polypeptide chain (except for prolines) and form critical hydrogen bonding networks within and 
between secondary structural elements of the protein, thus, even relatively subtle perturbations 
in the higher order structure of the protein will often affect the exchange rate of HDX at 
‘backbone’ amides 20–22,30,41,42. Also, at neutral pH, backbone amide protons undergo exchange 
at a rate that is amenable to measurement (i.e., ms – days, depending on the extent to which the 
intrinsic rate is attenuated by structure) 44.  In addition, the exchange at amide backbones is 
highly quenchable at low pH and low temperature allowing for monitoring of the dynamics at 
various time scales 45,46.  
     The chemistry of proton transfer at unprotected amide hydrogens is catalyzed by acid, base 
or water in some cases 28. In base-catalyzed HDX (predominant at pH above 3), the amide proton 
is removed by a hydroxide ion forming an amidate anion, which is then reprotonated by 
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deuterium oxide (Figure 2a). Acid catalysis (main below pH 3) has two competing pathways. The 
first possible mechanism involves deuteration of the amide nitrogen atom by D3O+, followed by 
proton abstraction by water, regenerating the acid (Figure 2b). However, since the amide oxygen 
is more basic than the amide nitrogen, the preferred pathway is initiated by the protonation of 
the amide oxygen atom, significantly acidifying the NH proton which is then removed by water, 
regenerating the acid (Figure 2c). The nitrogen atom in the resulting imidic acid is then 
deuterated by surrounding D3O+, and tautomerizes to the deuterated amide (Figure 2c). 
 
Figure 2. Schematic of base- and acid-catalyzed HDX of amide backbone protons in solution. (a) 
Base-catalysis, (b) acid-catalysis through N-protonation, (c) acid-catalysis via O-protonation. 
 
The chemical HDX rate constant (kch) for the amide hydrogen follows equation (1): 
                               𝑘ch = 𝑘𝑖𝑛𝑡,𝑎𝑐𝑖𝑑[𝐻3𝑂
+] + 𝑘𝑖𝑛𝑡,𝑏𝑎𝑠𝑒[𝑂𝐻
−] +  𝑘𝑖𝑛𝑡,𝑤𝑎𝑡𝑒𝑟[𝐻2𝑂]                        (1)  
where 𝑘int,acid and 𝑘int,base are the rate coefficients for the acid- and base-catalyzed exchange, and 
𝑘int,water is the intrinsic coefficient of water-catalyzed proton transfer 
28,42. The HDX rate is highly 
dependent on four factors – hydrogen bonding (strongest influence in folded proteins), solvent 
accessibility, pH and temperature 11,45,47,48,43,49. Other important factors include steric effects of 
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nearby amino acid groups, solvent composition of the HDX reaction and pressure in the system 
47,43,50. 
     Starting with temperature and pH, they define the “quenching conditions” – environmental 
settings that can significantly slow down the rate of HDX, so that accurate deuterium uptake 
profiles at various time points can be measured without the occurrence of back-exchange (loss 
of deuterium label) 12,25,32,51. The usual quenching conditions are pHmin (pH 2.5-3) and 0°C which 
slows the exchange reaction up to five orders of magnitude compared to pH 7 and 23°C 26,30,31,33.  
     Solvent abstraction of the amide hydrogen is always a rate limiting step, therefore, amide 
hydrogen involved in stable hydrogen bonding or deeply buried within the protein interior may 
elongate HDX reaction times from milliseconds to days 45,47.  HDX kinetics in folded polypeptides 
follows a model that amides can exist in either an exchange-incompetent (N-Hclosed) state due to 
hydrogen bond participation or solvent inaccessibility, or exchange-competent (N-Hopen) state 
where the proton can be abstracted 13,52. However, proteins are not static, and N-Hclosed hydrogen 
can become N-Hopen through various levels of structural unfolding or “breathing motions” 23,53. In 
this case, the model of HDX kinetics for a folded protein can be depicted as equation (2): 
                                                    𝑁𝐻closed 
𝑘op
⇌
𝑘cl
  𝑁𝐻open
𝑘ch
→
.
 𝑁𝐷𝑜𝑝𝑒𝑛 
𝑘cl
⇌
𝑘op
 𝑁𝐷closed                                                  (2) 
where 𝑘op and  𝑘cl are the rate constants for the opening and closing motions of the protein and 
𝑘ch is the intrinsic (‘chemical’) rate of exchange. Since proteins in solution are in equilibrium 
between open and closed states, the rate of HDX is mainly affected by the rates of 
unfolding/folding (𝑘op, 𝑘cl ) and chemical HDX rate constant, kch. Therefore, the exchange rate 
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constant (kHDX) of amides in structured proteins, where hydrogen bonding and solvent 
accessibility factors influence the rate of HDX, can be expressed by equation (3):  
                                                               𝑘HDX =
𝑘op × 𝑘ch
𝑘op + 𝑘cl + 𝑘ch
                                                                         (3) 
where 𝐾op is the equilibrium constant for the transition from ‘open’ state to ‘closed’ state 
23,53. 
When 𝑘op>>𝑘cl, the protein stays in the unfolded state and HDX is governed mainly by 𝑘ch 
21,53. 
However, under native-like conditions, 𝑘op<<𝑘cl as the hydrogen bonding network for much of 
the protein will be highly stable. In this case, the observed hydrogen exchange rate (𝑘HDX) 
simplifies to equations (4), (5), and (6): 
                                                                  𝑘HDX =
𝑘op × 𝑘ch
𝑘cl + 𝑘ch
                                                                                 (4) 
 
                                            𝑘HDX = 𝑘op (EX1)                    𝑘HDX =
𝑘op
𝑘cl
× 𝑘ch = 𝐾op𝑘ch (EX2)               (5), (6) 
Therefore, the two kinetic limits of exchange are: 1)  𝑘cl<<𝑘ch where refolding of the protein to 
the 𝑁𝐻closed state is much slower than the rate of HDX, and 2) 𝑘cl>>𝑘ch where refolding of the 
protein occurs much faster than HDX. These two regimes are called EX1 (𝑘cl<<𝑘ch) and EX2 ( 
𝑘cl>>𝑘ch), respectively, and can be depicted in MS spectra (Figure 3). In the EX2 regime (most 
common), the rate of HDX is much slower than the rate of refolding to the 𝑁𝐻closed state, so only 
a fraction of the available amide hydrogens will undergo deuterium exchange before the closing 
event. This results in a gradual increase in the m/z centroid of the isotopic envelope over time, 
where this isotopic envelope represents only one population of averaged closed and open states 
(Figure 3a) 12,54. In the EX1 regime, refolding process to the closed state is slower than the 
  𝑘cl ≪ 𝑘ch   𝑘cl ≫ 𝑘ch 
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exchange rate, so almost all amides become fully exchanged in a correlated manner. This is 
evidenced by a bimodal distribution - two m/z envelopes representing a fully-exchanged protein 
population (higher m/z species), and a non-exchanged one (lower m/z envelope) (Figure 3b). 
Over the course of deuterium exchange, all non-exchanged protein populations shift to the 
exchanged species (Figure 3b) 12,54. 
 
Figure 3. MS spectra of (A) EX2 and (B) EX1 kinetics during HDX-MS. Adapted from Guttman and 
Lee 54. 
 
     1.1.2.2. Common HDX-MS Workflow  
     The workflow of HDX-MS experiments can vary substantially depending on the information 
that a researcher wants to obtain, as well as, the type of instrumentation that is accessible. 
However, there is a common configuration of steps in HDX-MS, outlined in Figure 4, that gives a 
general overview of the most familiar type of HDX-MS experiment – “bottom up” HDX-MS. The 
workflow starts with sample preparation – the protein can be obtained through various means 
of expression and/or purifications and subsequently exchanged into a MS compatible buffer 12,51.   
Second step is HDX labelling – the protein sample is diluted into deuterated buffer, often a 10 to 
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20-fold dilution, in order to initiate isotopic exchange on the dynamic portions of the protein 
(Figure 4) 12,51. 
  
Figure 4. The outline of a general HDX-MS bottom-up workflow. It starts with sample preparation 
followed by HDX labelling and, after some chosen time, quenching with acid at 0°C and pH 2.5. 
Next, protein is digested into peptides which get desalted and separated thought C18 column 
attached to an LC. Finally, the percentage of deuterium uptake of each peptide is calculated, and 
results can be presented in the form kinetic plots or mapped onto a 3D protein structure. 
 
     Next, quenching of the HDX reaction is achieved by adding a pre-chilled (0°C) solution at pH 
~2.5 using either trifluoroacetic acid (TFA) or formic acid (FA) (Figure 4) 12,51. Quenching is 
followed by digestion of the protein which is usually implemented as part of the LC workflow 
(online digestion). Here, labelled protein sample first gets digested online using a LC pepsin 
column, and resulting peptides are subsequently desalted and concentrated in a trap column by 
washing with a low percentage of acetonitrile 12,51. This step is undertaken in a protic solvent 
resulting in the potential back-exchange of the labeled backbone amides, the first two amides 
undergo a rapid HD exchange and, therefore, omitted in analysis 12,51. Finally, peptides are 
released from the trap column to an analytical C18 column where they are separated via 
hydrophobic interactions with C18 stationary phase and eluted with a gradient of organic solvent 
in a ‘reversed-phase’ fashion 12,51. Eluted peptides are then ionized by electrospray and usually 
analysed by two main types of mass analyzers – time-of-flight (TOF) and orbitrap  55,56. Last but 
not least, the percentage of deuterium uptake of each peptide is calculated based on the isotopic 
distribution and results can be displayed in many forms, most commonly via kinetic plots and 
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heat-mapped 3D protein structures (Figure 4). To achieve multi-dimensional separation of 
labelled peptides, IMS can be coupled to MS measurements. The ion mobility cell can be thought 
of as a gas-phase analogue of gel electrophoresis, as it separates ions based on their size 57. IMS 
separation of peptides was used in this research to increase spatial resolution.  
 
      1.1.3. Time-Resolved Hydrogen-Deuterium Exchange Mass Spectrometry (TR-HDX) 
     Conventional HDX-MS discussed in section 1.1.2 is a powerful method to study protein 
conformational dynamics on a second to minute time scale, as it can go no lower than 10 s for 
the HDX reaction to occur before quenching. However, many of the folding intermediates during 
a folding pathway of a protein assemble on a millisecond to second scale which stroke a need for 
millisecond HDX-MS methodology. As with other HDX applications mentioned earlier, the first 
millisecond HDX studies were done using NMR in late the 1980s by Udgaonkar and Baldwin 58, 
and Roder et al. 59 where the early folding intermediates of ribonuclease A (RNaseA) and 
cytochrome c (cyt c) were described. Dharmasiri and Smith were the first to couple millisecond 
HDX to MS in their 1996 report studying the folding pathway of cyt c 60. Short mixing times were 
accomplished using a flow-quench protein fragmentation/MS method which allowed for 
measuring isotopic exchange rates of the most rapidly exchanging amide hydrogens 60. Further 
development in this field occurred in the Konermann Lab in 2003, when Simmons et al. 
introduced a continuous flow millisecond HDX-MS device to study the conformational dynamics 
of myoglobin (Mb) under mildly denaturing conditions (27% acetonitrile, pH 9.3) with 
development of a detailed kinetic model 61. In order to provide spatial information after labeling, 
the Wilson Lab coupled this continuous flow millisecond HDX-MS device onto a microfluidic 
10 
 
platform accommodating online proteolytic digestion 62–64. This time-resolved electrospray 
ionization HDX-MS (TRESI-HDX) method from the Wilson Lab has been used in current research 
(with some further modifications, see section 2.8) and the general setup is depicted in Figure 5. 
The millisecond HDX reaction time is possible due to a rapid kinetic mixer where protein, flowing 
from the inner yellow channel with a sealed end and 2mm notch, mixes with deuterium flowing 
from the outer channel (Figure 5) 62–65. Depending on how far the protein channel is pulled back, 
protein and deuterium react at different time points before being quenched by acid (Figure 5) 62–
65. The deuterated quenched protein sample is then digested in a downstream reaction chamber 
by acid resistant proteases (pepsin, protease XII, etc.) linked to agarose beads, and, resulting 
peptides are introduced to MS through ESI (Figure 5) 62–65.  
 
Figure 5. A schematic representation of a continuous flow TRESI-HDX-MS setup on a 
microfluidic chip. From left to right, protein sample is introduced in the inner (yellow) capillary 
and exits through the kinetic mixer to meet with deuterium flowing through the outer channel. 
The protein line can be pulled back (dotted black arrow) allowing for various HDX reaction times. 
Acid channels quench HDX and the protein is digested in a downstream reaction chamber. 
Peptides are ionized by ESI and introduced into the MS. Adapted from Lento et al. 2016 65. 
 
     TRESI-HDX-MS has proved its various applications with numerous research publications 
depicting millisecond conformational changes in protein-RNA/DNA interaction, enzymatic 
transition states, intrinsically disordered protein folding/misfolding intermediates, and antibody-
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antigen interactions 37,38,66–68 . For example, Brown and colleagues were able to  characterize the 
changes in dynamics at a 2 s time scale during RNA binding to RRM2 motif of human La protein, 
and found some key differences in conformational dynamics of La protein when it binds to single-
stranded versus double-stranded RNA 38. In another study by Zhu et al. in 2015, TRESI-HDX-MS 
was used to elucidate the shifts in conformational dynamics of intrinsically disordered protein 
(IDP), tau, when it is hyperphosphorylated 69. The HDX measurements were taken from 42 ms to 
12 s showing some increases in deuterium uptake in a few hexapeptide regions of hyper-
phosphorylated tau (compared to native), suggesting a more open and extended confirmation 
which can easily be rationalized as enhancing amyloidogenic propensity 69. Here, Zhu and 
colleagues have shown that TRESI-HDX-MS is a powerful approach for probing the structural 
dynamics of non- to weakly structured regions of proteins on a millisecond to second scale and 
ideal for studying IDPs.  
 
     1.1.3.1. Application: Intrinsically Disordered Protein Domains/Proteins  
     IDPs are a class of proteins lacking a fixed or ordered three-dimensional structure, meaning 
that they can obtain a variety of conformational ensembles with no prevalence to any particular 
3D structure 70,71. IDPs have become an important target for structural dynamics research – only 
recently it was noticed how crucial they are in transcriptional regulation, translation and cellular 
signal transduction 71–75. Even though many IDPs have been discovered in last few decades, not 
many experimental analytical tools are available for characterization of their behaviour 70,71.  X-
ray crystallography cannot provide information on unstructured states, but can only indicate if 
there is an unstructured region by showing the presence/absence of electron density in these 
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areas 70,71,76. NMR is by far the  key experimental method for obtaining systematic site-specific 
information on IDPs, but, again, limitations of the NMR technique like molecular size restrictions 
and the large amount of sample required make it difficult to study different variations of IDPs, 
especially their transient interactions with protein complexes 27,33,34. Alternatively, TRESI-HDX-
MS has no size limitations, works with even nanomolar concentrations of protein, and is able to 
provide good spatial resolution (peptide level to even amino acid resolution if using an electron 
capture dissociation, ECD, cell in MS) 69,77,78. Last but not least, TRESI-HDX-MS provides 
conformational dynamics information on a millisecond scale for studying the transition state 
species of IDPs and the most favourable conformational ensembles if they exist 69,77,78. TRESI-
HDX-MS provides a great alternative to NMR and other conventional bioanalytical techniques 
(circular dichroism (CD), hydrodynamic measurements, fluorescence spectroscopy, vibrational 
CD spectroscopy and RAMAN spectroscopy) making it a powerful tool to characterize the 
disordered structural behaviour of IDPs. 
 
1.2. Nanodisc Technology – Soluble Lipid Bilayer Systems for Structural and 
Functional Studies of Membrane Proteins 
     1.2.1. Major Complication in Membrane Protein Structural Biology Research 
     The importance of membrane proteins (MPs) in biological processes is huge. Around 30% of 
all proteins in eukaryotic cells are MPs, and almost 50% of all known small molecule drugs target 
this class of proteins 79–81. MPs are responsible for many vital functions in a cell; they are 
receptors that relay signals between the cell's internal and external environments, they are 
transporters that move molecules and ions across the membrane, many are enzymes with 
various catalytic functions, while others play a role in cell adhesion and other processes crucial 
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for cell’s survival 81–87 . However, little is known about this class of protein, as they present a great 
challenge in structural biology research. The difficulties in studying MPs arise due to many 
reasons. Since MPs are present at very low concentrations, it is quite rare that a single protein 
dominates the constituent of a membrane, therefore, the MPs’ yield from extraction and 
purification processes is quite low 88,89. Although genes for MPs can be cloned into bacterial 
plasmids for further recombinant expression, post-translational modifications (PTMs) required 
for some MPs are not attainable in these expression systems 88–90. The other problem with MPs 
is that they are a part of a very complex and unique matrix – the mosaic bilayer of a membrane, 
which prevents standard biophysical techniques like NMR, CD, X-ray from obtaining high 
resolution results 88,89. In many cases, MPs must be taken out from it’s native mosaic bilayer 
which can lead to a change in their structural properties 88,89. Also, purification protocols for the 
extraction of MPs can be very challenging and time consuming 88,89. Last but not least, the 
hydrophobic character of MPs prevents their solubilization in aqueous solutions leading to 
aggregation issues starting from the purification process up until the final steps of analytical 
experiments that are mostly solution-based 88,89. Despite all the difficulties with studying MPs, 
they still remain an active target of research which has been rapidly developing over the last few 
decades. 
 
     1.2.2. “Old Generation” Artificial Membrane Systems 
     Since no conventional biophysical technique is sufficient enough to deal with complex mosaic 
bilayers, MPs must be transferred to a more tractable environment for experimental study. The 
first of these type of environments were detergents – amphipathic molecules consisting of polar 
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head groups and hydrophobic chains which can spontaneously form spherical micellar structures 
in aqueous solutions. There are many types of detergents that have been developed over the 
years which are now classified into four modules based on their charge state: 1) anionic (for 
example sodium dodecyl sulphate (SDS) and the bile salts such as cholate and deoxycholate), 2) 
cationic (cetyltrimethylammonium bromide or CTAB), 3) zwitterionic (3-[(3-cholamidopropyl)-
dimethylammonio]-1-propanesulfonate or just CHAPSO), and 4) nonionic (like the 
polyoxyethylene series of detergents such as Triton X-100) 88,89,91,92. Without going into the 
details about each module, it is worth noting that nonionic and zwitterionic detergents have 
become very popular in MP research as proteins retain their function after solubilization 88,89,91,92. 
The basic principle of MP extraction by detergents is represented in Figure 6.  
 
 
Figure 6. A schematic representation of various stages of solubilization of biological 
membranes by detergents. Biological membrane (A) is mixed with detergent starting the process 
of perturbation of lipid bilayer with detergent molecules followed by penetration into the 
membrane (B). More and more detergent molecules penetrate the membrane resulting the in 
membrane bilayer being disrupted (C). Finally, high detergent concentration forms 
heterogeneous complexes of detergent, lipid and protein  - mixed micelles of lipid and detergent 
and protein and detergent (D). Adapted from Kalipatnapu and Chattopadhyay 91. 
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      Assuming detergent concentration is equal or above the critical micelle concentration (CMC), 
detergent molecules first saturate the lipid bilayer (Figure 6B), then solubilize both the 
hydrophobic and amphipathic molecules in the solution (Figure 6A) resulting in the formation of 
water-soluble protein-detergent complexes, detergent and detergent-lipid micelles (Figure 6C) 
91,92.  Despite having many advantages like great variability of detergents and relatively low cost, 
detergent systems are a poor mimic of the native membrane environment and frequently 
destabilize and inactivate protein over time 91. In addition, many detergents can complicate 
spectra or exhibit incompatibility with MS, NMR or X-ray and other techniques. Especially in the 
case of MS, most detergents cause signal suppression of a MP sample – detergents compete for 
maximum ionization potential in ESI and detection capability of a protein lowers 93,94. In order to 
resemble a native-like environment for MPs, the field moved towards mixed lipid – detergent 
systems like bicelles and liposomes (Figure 7). 
Figure 7.  A cartoon representation of some key lipid membrane mimetics. From left to right: 
detergent micelle, liposome, lipid – detergent bicelle, non-covalent structure of lipid and 
membrane scaffold protein  - nanodisc, and styrene maleic acid co-polymer lipid particle 
(SMALP). Detergent is represented by blue color ball pins, lipid by green ball pins, and organic 
polymers by dark blue bands. Cylinders represent α-helices of proteins. Adapted from Milić and 
Veprintsev 95. 
 
     Bicelles can be described as microscopic disks where a bilayer patch of lipid is encircled by a 
“rim” of detergent molecules (Figure 7) 89,96. Bicelles are prepared by mixing long-chain lipids 
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such as dimyristoylphosphatidylcholine (DMPC) with shorter chain (tail) edge-stabilizing 
detergents like CHAPSO in 4:1 to 1.5:1 lipid:detergent molar ratios 89,96. Detergents can be 
completely eliminated from bicelles if short chain lipids such as dihexanoylphosphatidylcholine 
(DHPC) is used as a “rim” making this membrane mimetics even more native-like 89,96. Bicelles 
provide several advantages over detergent micelles. They represent a lipid bilayer which is a 
more native-like environment for structural studies of MPs, and they are much easier to work 
with using NMR and X-ray techniques since less detergent is present and bicelle aggregate sizes 
are sufficiently small to be aligned in a magnetic field 89,96. However, bicelles exhibit many 
disadvantages especially for MS research: 1) even smaller amount of detergent will cause signal 
suppression, 2) the lipid-detergent or lipid-lipid ratios must be strictly preserved during the 
experiment to prevent bicelle disassembly and avoid any phase transitions, 3) the current lipid 
compositions of bicelles is very limited, as only DMPC-CHAPSO and DMPC-DHPC works 97,98.    
     Another popular lipid membrane mimetic are liposomes (Figure 7) – small artificial vesicles of 
spherical shape that can be created from natural phospholipids with the help of detergents 89,99. 
Just like bicelles, liposomes create much more of a native-like environment for MPs (lipid bilayer), 
but they are more stable, and they exhibit more variation in lipid composition 89,99. But then 
again, the reconstitution of MPs in liposomes is though a detergent-mediated pathway leaving 
detergents to interfere with downstream MS or NMR analysis 89. Also, there is always a concern 
of how evenly the MPs are distributed in liposomes and in what exact direction and topology – 
all of these factors affect MPs function. For example, membrane transporters must be inserted 
in a single transmembrane orientation to ensure that pumping of substrates occurs in the correct 
direction: inside-out or outside-in 100. Detergent micelles and lipid–detergent systems like 
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bicelles and liposomes are good tools for solubilizing MPs for further structural and functional 
studies, but as discussed, they also have many disadvantages. The most critical disadvantage is 
that these artificial membranes disassemble at lower concentrations 101. This problem is most 
notable in MS studies as better signal-to-noise ratio in modern mass spectrometers is obtained 
on lower a concentration (nM to µM) scale. Therefore, the search for more advanced artificial 
membranes became even more important in recent years leading to the development of “new 
generation” membrane mimetics.   
 
     1.2.3. Nanodiscs – “New Generation” Artificial Membrane Systems   
     Nanodiscs are small nanoscale lipid bilayers wrapped around by a belt of one or two α-helical 
proteins (Figure 7) 102–106. This technology was developed by Sligar and coworkers at the 
University of Illinois in 2007 105. Seeking for more “natural” membrane mimetics, the concept of 
nanodiscs originated from the architecture of high density lipoproteins (HDL) in human cells 104. 
These particles are key transporters of fat molecules around the body and resemble a ball shape 
of various sizes containing cholesterol esters, lipids and proteins 104. However, the transient form 
of HDLs is roughly discoidal and stabilized by the amphipathic apolipoprotein A-I (Apo-AI) 104. The 
Sligar lab genetically engineered the Apo-AI sequence to produce a set of different sized 
amphipathic helical proteins, termed membrane scaffold proteins (MSPs), which were capable 
of self-assembly into discoidal phospholipid bilayers or nanodiscs 104,107.  Right away, nanodiscs 
displayed distinct advantages over the “old generation” model membranes such as liposomes 
and detergent-stabilized micelles 105. First of all, there is a vast variety of nanodisc sizes (from 4 
to 12 nm) since MSP can be truncated to a variety of lengths – this maximizes the pool of MPs 
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(large or small) available for study 108. Second, nanodisc particle size distribution is quite 
monodisperse (nanodisc size within single preparation is very similar) and consistent (nanodisc 
size are the same between different preparations) as the protein belt set boundaries for the 
dimensions of the bilayer 104,107. Third, the protein belt also assists in long-term stability of a 
nanodisc – an empty nanodisc can be stable for up to 2 years at -80°C. Fourth, the lipid content 
of a nanodisc can come from various sources – synthetic or natural lipids 109. The most popular 
synthetic lipids for nanodisc assembly are phosphatidylcholines (PC-lipids) like DMPC (14:0), 
DPPC (16:0) and POPC (16:0-18:1), as well as mixtures of PCs with charged phospholipids such as 
phosphatidylserines (PSs), phosphatidylglycerols (PGs), phosphatidylethanolamines (PEs), and 
phosphatidylinositols (PIPs) 109. Cholesterol has also been reported to be included into the 
nanodisc lipid bilayer for research on MPs interaction and fusion with membranes 110,111. Fifth, 
nanodisc stability is independent of the critical micelle concentration and does not disassemble 
upon dilution. On the contrary, Hu and colleagues have found that dilution of nanodiscs induce 
disk coalescence meaning two or more nanodiscs fuse into one bigger disc 112. This is not ideal if 
the monomeric state of an MP is researched, but the bigger disc still helps all MPs to stay soluble 
and prevent their aggregation. Sixth, a few research papers  show evidence that nanodiscs better 
reflect the complex phase transition behavior of biological membranes than conventional model 
membranes 113,114. Last but not least, MSP purification, as well as, nanodisc assembly is a 
relatively easy and straightforward procedure.  
     The nanodisc assembly protocol will be discussed in more detail in sections 2.2 and 2.5, 
however the basic outline of two possible routes for MP extraction into nanodiscs are shown in 
Figure 8 115. Here, route 1 is the standard method for self-assembly of an MP into a nanodisc, 
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where, first, the biological membrane gets solubilized by detergent and MPs are purified (Figure 
8) 115. Then, the target MP (green) is mixed with the MSP (violet) and lipids at the correct 
stoichiometry (Figure 8) 115. Right after, detergent is removed by hydrophobic beads and 
nanodiscs are assembled with the MP inside, ready for future analysis (Figure 8) 115. Route 2 is an 
alternative way for MP extraction, where the membrane tissue gets solubilized by excess lipid 
and scaffold protein, followed by rapid detergent removal (Figure 8) 115. This results in placement 
of the target MP (green), together with other MPs (gray) from the membrane into the nanodiscs 
(Figure 8) 115. Nanodiscs with target MPs (green) are purified from nanodiscs with unwanted MPs 
(grey) often by means of affinity chromatography (Figure 8) 115.  
                               
Figure 8. A diagram depicting the process of membrane protein extraction by nanodiscs. Route 
1 (left side) is a standard protocol where membrane tissue is solubilized and target MP (green) is 
purified. Later, this MP is mixed with correct stoichiometry of lipid and MSP (violet) inducing 
nanodisc assembly around the MP though detergent removal. Alternative route 2 (right side) 
starts with mixing up biological membrane with excess lipid and scaffold protein which stimulates 
membrane solubilization. Right after, detergent is removed from solution facilitating nanodisc 
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formation around all MPs (target or not). Nanodiscs with target MPs are purified from nanodiscs 
with unwanted MPs. Adapted from Denisov and Sligar 115. 
 
     Over the last 10 years, nanodiscs became a very popular membrane mimetic for different 
biophysical analytical techniques – fluorescence spectroscopy, NMR, surface plasmon resonance 
(SPR), electron microscopy, X-ray crystallography and, of course, MS 106.  It is no wonder that 
nanodisc technology quickly found a great application in HDX-MS. However, the general HDX-MS 
bottom-up workflow shown in Figure 4 was slightly modified – right after the quenching step the 
nanodisc is disassembled by addition of cholate followed by protein digestion and adsorption of 
lipid-detergent mix onto ZrO2 resin 116,117. One of the examples of where nanodisc HDX-MS 
technology has proved to be very useful was the study conducted by Parker and colleagues on 
conformational dynamics of gamma (γ)-glutamyl carboxylase (GGCX) during binding to high-
affinity consensus propeptide (pCon) belonging to the Vitamin K Dependent (VKD) class of 
proteins 118. The previously used sample preparation methods for GGCX had failed due to 
aggregation, oligomerization, and precipitation, but nanodisc technology have resolved these 
issues and have helped to obtained interesting HDX results 118. The binding event of nanodisc-
bound GGCX to pCon has shown multiple decreases in deuterium uptake throughout many 
regions of GGCX , as well as, regions known to bind pCon 118. The HDX profile proved the ligand 
binding event and indicated a more compact structure (less conformationally dynamic) for GGCX 
when in complex with pCon 118. This study has shown how nanodiscs were able to provide a 
stable, native-like environment for MP conformational studies using MS demonstrating again the 
advantages of “new generation” membrane mimetics. 
     In addition to nanodiscs, another representative of “new generation” artificial membrane 
systems are SMALPs. SMALPs exhibit the same discoidal shape as nanodiscs (Figure 7), but the 
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protein belt is replaced by styrene maleic acid co-polymer (SMA) 119. There are few advantages 
of SMALPs over nanodiscs – one of which is that no detergents are used in solubilization of the 
biological membrane, as SMA inserts into the membrane itself and forms small, soluble 
nanoparticles containing proteins and lipid bilayer 120. Also, no synthetic lipids are needed, as 
SMALPs cut off patches of the biological membrane preserving the complexity of the mosaic 
bilayer and achieving an even greater “nature-like” environment for MP studies 120. In this 
research, however, only nanodiscs were used.   
     To conclude, “new generation” lipid mimetics more closely resemble the complex mosaic 
bilayer of biological membranes than the “old generation” allowing for a smoother transition of 
MPs from their native environment without any functional perturbations. 
 
1.3. Intrinsically Disordered Proteins in Human Diseases 
     1.3.1. Overview 
      The structure - function paradigm which implies that a protein with a unique function is 
defined by its 3D structure has been a strong belief for over a century in the field of biochemistry 
121. Nonetheless, intense research of the human proteome and biology of many human disorders 
in the last 20 years have clearly shown that the lack of stable tertiary and/or secondary structure 
does not prevent proteins from being biologically active 70,72,75,121–123. More notably, IDPs and 
intrinsically disordered protein regions (IDPRs) are quite abundant in nature and many crucial 
cellular functions such as signalling, regulation, and transportation processes would not be 
possible without them 121,124–126.  The functional advantage of IDPs and IDPRs from functional 
folded proteins is in their structural plasticity and conformational adaptability 121. Their ability to 
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rapidly change conformations in response to different environments permits them to fold 
differently and interact with different binding partners allowing for a wide set of functions for 
different cellular contexts 70,72,75,121–123. Since IDPs/IDPRs are usually fluctuating between two 
major protein forms, functional - folded  and functional - intrinsically disordered, misfolding (the 
failure of a peptide/protein to adopt its functional conformational state) can lead to a broad 
range of human diseases known as protein conformation or protein-misfolding diseases 121,124. 
Certain forms of cancer, Parkinson’s disease (PD), dementia, Alzheimer’s disease (AD), Down’s 
syndrome, multiple system atrophy (MSA), prion and cardiovascular disease, as well as, Type II 
diabetes are the most common protein-misfolding diseases caused by various IDPs/IDPRs 
conformational misfoldings 121,124. The hallmarks of protein-misfolding diseases are usually 
aggregation and/or fibril formation, loss of normal function by a protein and gain of a toxic one. 
For example, the partially folded state of amyloid β-protein (Aβ) promotes protein fibrillation 
generating the cascade of neuropathogenetic events that results in AD 127. Another example is 
loss of function of a very important IDP in cancer prevention, p53, where the interaction with 
Mdm2/Hdm2 averts it from binding to various transcription factors, and begins the process of 
p53 degradation in the nucleus and cytoplasm 124,128. When p53 function is lost and no signal 
transduction occurs, a cell often undergoes cancerous transformation 124,128. The high abundance 
of intrinsic disorder in proteins involved in various diseases gives the wrong impression of 
IDPs/IDPRs being very unstable and  unpredictable proteins incapable of proper folding 
mechanisms to carry their functions. Actually, functions of IDPs/IDPRs are tightly controlled by 
various cellular processes like induced folding upon interaction with the corresponding binding 
partners, alternative splicing (AS), and various PTMs 121,124–126. When the proper line of control is 
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failing and/or the cell environment undergoes perturbations, IDPs/IDPRs are structurally 
“confused” and the capability of recognizing proper binding partners is decreased, forcing them 
to stay in partially-folded conformations (misfolded) longer and from non-functional and deadly 
aggregates 121. Therefore, IDPs/IDPRs are very important and reliable proteins in many biological 
processes that pose no harm to the healthy state of a cell, unless poorly controlled or 
environmental conditions have been changed.  
     The ultimate goal is to understand what causes the loss of IDP/IDPR regulation - the root cause 
of misfolding, as well as, to validate the most toxic “misfoldants” in order to create specific drugs 
against them. Fortunately, IDP/IDPR studies are getting more and more attention from the 
scientific community resulting in the fast development of techniques that will help us know more 
about this class of proteins and their roles in human diseases.  
 
     1.3.2. Parkinson’s Disease (PD) 
     One of the largest groups of misfolding diseases is neurodegenerative disorders which are 
defined by the loss of neurons within the brain and/or spinal cord 124,129. The two most common 
neurodegenerative disorders are Alzheimer’s and Parkinson’s diseases 129. The latter one is a 
motor-impairment disorder with a prevalence close to 2-4% after the age of 60 130,131. The main 
symptoms of PD (can occur separately or together) are tremor at rest, rigidity, akinesia or 
bradykinesia, and postural/gait instability 130,132. Sometimes patients may develop depression 
and non-motor symptoms like anxiety, fatigue and sleep disturbance 133.  This disorder can be 
either genetically inherited as an autosomal dominant/autosomal recessive trait or gained over 
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time by means of mutated genes encoding α-synuclein (αSN), parkin and ubiquitin carboxy-
terminal hydrolase L1, and/or any perturbations in αSN’s concentration or its conformational 
dynamics in the cell 125,130,134. The involvement of αSN, an IDP, has a major influence on the 
development of PD and will be discussed in detail in section 1.3.3.  
     PD’s main pathological hallmarks are the formation of substantial protein aggregates like Lewy 
bodies (LB) and Lewy neurites (LN), and massive death of dopaminergic neurons in pars compacta 
of the substantia nigra (substantia nigra is marked by a red circle in Figure 9) 130,134,135. The 
consequence of dopaminergic neurons’ death causes major implications to basal ganglia 
striatonigral direct pathway which is employed for initiation of movement  (Figure 9) 136,137.  
    
Figure 9. A cartoon representation of the simplified basal ganglia striatonigral direct pathway 
in a human brain (midsagittal plane cut). (1) The pathway starts with dopaminergic neurons 
sending dopamine to the striatum. (2) The striatum gets activated and releases GABA to globus 
pallidus in the basal ganglia. (3) Activated thalamocortical pathway (in thalamus) transmits signal 
to cortex for initiation of movement 136,137. 
 
      In a healthy brain, pars compacta is formed by dopaminergic neurons which send excitatory 
input to the striatum (Figure 9) 136,137 . The striatum is a connector between substantia nigra and 
the rest of the basal ganglia nuclei (Figure 9) 136. It receives dopamine, gets activated, and 
releases gamma-aminobutyric acid (GABA) neurotransmitters into the globus pallidus (Figure 9) 
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136,137. As a result, the thalamocortical pathways (in the thalamus) get activated and transmits 
motor neuron signals to the cerebral cortex to allow the initiation of movement (Figure 9) 136,137. 
In a Parkinson’s brain, dopaminergic neurons in pars compacta die and there is less and less 
dopamine transmission to the striatum which causes motor impairment (Figure 9) 136,137. Note 
that this is a very simplistic explanation of basal ganglia circuit only shown here for understanding 
the overall significance of dopaminergic neurons in healthy motor functions.  
     Despite great strides made in understanding PD in recent years, diagnostics and treatment of 
this disorder remains very challenging 132. With the recognition of several premotor features and 
potential biomarkers, Parkinson’s diagnosis is still primarily based on clinical motor findings 
which is already in a progressive state of the disease 132. The most effective treatment is 
carbidopa-levodopa combination therapy which does not provide a cure but only acts to mask 
the symptoms, and most patients develop dyskinesia after 5 to 10 years of this treatment 132. It 
is important to continue research on the causes and roots of Parkinson’s disease, as well as, the 
possible ways of treating this incurable neurodegenerative disorder. 
  
     1.3.3. α-Synuclein and Its Role in PD 
     Substantial evidence links αSN, a small highly conserved presynaptic protein with unknown 
function, to both familial and sporadic PD 125,138–146. αSN in not only the major component of 
LB/LN, but mutations in the SNCA gene encoding for αSN can cause an inherited form of PD, as 
well as, overexpression of normal (non-mutated) αSN can increase the risk of developing this 
disorder in sporadic, or non-familial, cases 125,135,138–146.  Being a typical IDP, αSN is capable of 
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adopting a number of different conformational states depending on cellular conditions and 
presence of cofactors – it has over 50 ligands where 30 of them are proteins 147–149. The role of 
this protein in neurons is vaguely known but recent studies suggest that αSN is very important in 
cell signalling processes and works as a molecular chaperone for the SNARE complex which plays 
a key role in compartmentalization, storage, and recycling of neurotransmitters 139,143,147–149. This 
protein is abundantly expressed in the nervous system, comprising 1% of total cytosolic protein 
suggesting an importance in day-to-day functions of neurons, presumably as a modulator of 
synaptic transmission 125,140. 
     Unfortunately, as many other IDPs, misfolding of αSN into aggregation-prone intermediates, 
gain of toxic function and toxic loss of function cause neurotoxicity in dopaminergic neurons and 
consequent pathogenic effects leading to PD development 146. There are many ways in which 
αSN’s misfolding and toxic function can affect neurons. It can behave as a prion by being exported 
from a cell to start the aggregation process in other cells 150. It can polymerize in protofibrils that 
form elliptical or circular amyloid pores which are capable of puncturing cell membranes, 
resulting in the release of cellular contents and cell death 151,152. Most relevant to this research, 
is αSN’s role in vesicle storage and transportation of dopamine and how misfolding of this IDP 
results in oxidative stress leading to neuronal cell death 130,153,154. In dopaminergic neurons of 
substantia nigra pars compacta dopamine is the main neurotransmitter, and, as soon as, 
dopamine is synthesized it gets packed into small membrane vesicles either for storage or 
exocytosis (Figure 10) 125,130,146,153,154. The formation of these synaptic vesicles from early 
endosomes is regulated by αSN through interaction with phospholipase D2 (Figure 10) 130. For 
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proper vesicle construction and transportation, the formation of secondary α-helical structure by 
αSN on the surface of the lipid bilayer is crucial (Figure 10) 125,138,146,153,154. 
Figure 10. Proposed mechanism of dopamine storage and transportation in presynaptic 
dopaminergic neurons. Newly synthesized dopamine is packed into small membrane vesicles 
with the help of α-helically folded αSN and its interaction with phospholipase D2 (PLD2) 155. 
Dopamine is then released into the synaptic cleft also with the help of αSN. If αSN is misfolded, 
less or no vesicle formation occurs leading to self-prone oxidation of dopamine in the cytoplasm. 
Free radical and oxidative species like H2O2, O2•-, and dopamine–quinone by-products (DOPAC) 
cause oxidative stress and subsequent cell death. Adapted from Lotharius et al 138. 
 
     Any perturbation of αSN folding will expose hydrophobic regions that are prone to stack into 
hydrophobic β-sheets, which later lead to the formation of fibrils and Lewy bodies 125,130,146,153,154. 
Aggregated αSN can no longer assist in vesicle formation and transportation which results in 
accumulation of dopamine in the cytoplasm 125,130,146,153,154. Dopamine in the cytoplasm is 
predisposed to auto-oxidation creating toxic hydrogen peroxide (H2O2), superoxide radicals   
(O2•-), and dopamine–quinone by-products or 3,4-dihydroxyphenylacetic acid (DOPAC) (Figure 
10) 138. Oxidative stress caused by these radicals and by-products trigger neuronal death 138. 
Many models were proposed on the mechanism of αSN’s misfolding, which will be discussed later 
in section 1.3.3.2, but no particular conformational intermediate has yet to be analyzed. Even 
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though improper folding of αSN is a primary biomarker of PD, little is known about this IDP and 
the research that started almost 20 years ago continues.   
     1.3.3.1. Structural properties of αSN 
      αSN is a relatively small protein composed of 140 amino acids. Its amino acid sequence can 
be divided into three distinct regions. First is the N-terminus amphipathic region (residues 1 to 
60) which contains four 11-amino acid imperfect repeats with conserved motif KTKEGV (Figure 
11) 125,146. This region has a high propensity of forming amphipathic helices, especially in the 
presence of lipid membranes. Second is a hydrophobic region (residues 61-95) or so-called non-
amyloid-beta component (NAC) (Figure 11) 125,146. The NAC region is highly involved in αSN’s 
aggregation when acquiring beta-sheet structure 125,146,156. Third is the C-terminal acidic tail 
(residues 96-140) which is enriched in negatively charged and proline amino acids helping this 
region to remain unfolded (Figure 11) 125,146,156.  
 
Figure 11. Three distinct regions of αSN’s amino acid sequence. The N-terminal region consisting 
of the first 60 residues is amphipathic and accounts for binding phospholipids, the hydrophobic 
region between amino acids 61 and 95 is also called the non-amyloid-beta component (NAC), and 
the C-terminal region (residues 96 to 140) is negatively charged and usually remains 
unstructured. 
 
     In the native form, the NAC domain appears to be partially protected by the long-range 
interactions (hydrophobic and electrostatic contacts) between the N- and C-terminus, as well as 
contacts between the C-terminus and NAC 156,157. These interactions provide a substantial degree 
of compactness to αSN preventing hydrophobic regions of NAC to be exposed for aggregation 
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156,157. Of course, mutations in αSN, changes in environmental conditions, and PTMs may disrupt 
this native compactness inducing misfolding and aggregation 156.  
     αSN falls into a specialized class of IDPs – natively unfolded proteins, as this protein is 
extremely flexible, relatively noncompact, and its structure is shown to be devoid of significant 
amounts of secondary order under physiological conditions 125,158. For its ability to adopt a series 
of different conformations depending on the environment (temperature, salt, pH etc.), it was 
called protein-chameleon 159. Figure 12 represents the series of different conformations that αSN 
is capable to adopt 159. 
Figure 12. Series of different conformations that αSN, protein-chameleon, is able to adopt in a 
template-dependent manner. αSN’s phenomenal plasticity in response to different 
environments give rise to many conformational states of this small IDP: (from top left clockwise) 
natively unfolded monomer, partially folded intermediate, β-structured monomer, α-helical 
monomer, β-structured oligomer, α-helical oligomer, spheroids, doughnuts and crescents, 
amorphous aggregates, and amyloid-like fibrils. Adapted from Uversky, 2003 159. 
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     1.3.3.2. αSN’s Conformational Behaviour in The Presence of Lipid Membranes 
     The membrane-assisted folding of αSN is not only important for the formation of presynaptic 
membrane vesicles, but also for prevention of its aggregation into LBs 78. In the presence of a 
lipid bilayer, αSN acquires its α-helical structure in two main steps: step 1 – the first 20 amino 
acids  on the N-terminus insert themselves as a helix into the phospholipid bilayer, step 2 – the 
rest of the amphipathic region of αSN and NAC region undergoes a coil/helix transition 78.  While 
the first two regions of αSN bind lipids through the four 11-amino acid imperfect repeats with a 
conserved motif KTKEGV, the C-terminal tail remains unstructured and is thought to be a protein-
protein interaction motif 125. Figure 13 represents an axial view of the first 102 amino acids of 
αSN that form a helix upon interaction with the membrane. αSN resides on the lipid bilayer in a 
way that hydrophobic residues like Gly, Ala, Val, Leu, Ile, Phe, and Met are embedded into the 
hydrophobic region of the bilayer, positively charged Lys and His are on the border of the 
hydrophobic and polar environments and stabilize the helix through electrostatic interactions, 
and the remaining polar amino acids are on the outside of the lipid bilayer (Figure 13) 160. 
Figure 13. An axial view of the first 102 αSN residues when bound to a phospholipid bilayer. 
Hydrophobic residues of αSN are embedded into the hydrophobic part of a bilayer, charged 
amino acids stabilize the helix just outside of lipid bilayer via electrostatic interactions, and polar 
residues do not interact with lipids at all. Adapted from Auluck et al.160  
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     Over the years, some models have been proposed trying to explain the structural behaviour 
of αSN when interacting with synaptic vesicles. Some of the principal models were made by Igor 
Dikiy and David Eliezer 141. From CD and NMR studies, this IDP in the presence of SDS micelles 
exhibited a helical structure made up of two curved antiparallel helices connected by an 
extended linker of residues 38 to 44 – this broken-helix state is visualized in Figure 14 141,161–163. 
However, using bigger membrane mimetics like bicelles showed that the lipid-binding domain of 
this protein was found to adopt a single extended helix (also shown in Figure 14) suggesting a 
great structural dependence on the size of the membrane system 141,164,165 . Based on these two 
states and many literature references, the model depicted in Figure 14 was proposed.  
      In the cell, αSN is in equilibrium between two sates – intrinsically disordered (free protein) 
and membrane bound (helix state) (Figure 14) 141. αSN in an intrinsically disordered state can 
obtain many conformations, more or less extended, as any other IDP 141. However, when αSN 
folds onto the vesicle’s membrane it obtains an extended-helix, which can then interconvert into 
the broken-helix state upon approach of the synaptic vesicle to the plasma membrane (Figure 
14) 141. Therefore, the broken-helix state works as a sensor for docked vesicles playing an active 
role in vesicle fusion either by regulating the activities of other proteins or by membrane 
remolding required for the fusion process 141. All of these three conformational states – broken-
helix, extended-helix and free protein do not pose any pathological behaviour and are healthy 
for cells 141. The conformations that are dangerous and more prone to aggregation are folding 
intermediates as αSN transitions from one state to another (Figure 14) 141. In these intermediate 
states, the N-terminal region remains bound and helical, while the C-terminal region of the lipid-
binding domain is unstructured. This opens up the NAC and C-terminal regions for intermolecular 
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interactions facilitating formation of the beta-sheet rich aggregates – hallmarks of PD (Figure 14) 
141. Dikiy and Eliezer suggest that all aspects of this model must undergo extensive testing before 
it can be considered to reflect the actual behavior of αSN in vivo, but the model is very consistent 
with many existing observations regarding the properties and potential functions of aSN 141. 
Figure 14. Model for the correlation of different conformational states of αSN when interacting 
with synaptic membrane vesicles in dopaminergic neurons. Poorly structured protein regions 
are depicted as solid lines, while helical regions are filled cylinders. Membrane bilayers are 
indicated as double black lines with dashes. The intrinsically disordered states of αSN are in 
equilibrium with the vesicle-bound extended-helix state. The latter can convert to the broken-
helix state upon approach to the pre-synaptic plasma membrane. Transitions that are a part of a 
healthy state are indicated by black double arrows, and those that are part of pathological 
behavior are indicated by orange double arrows. Adapted from Dikiy and Eliezer 141.  
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     1.4 Research Objectives 
     To better understand Parkinson’s disease, the conformational dynamics of αSN’s folding and 
misfolding pathways in the presence or absence of phospholipid membrane must be accurately 
determined. Structural analysis of αSN using high-resolution biophysical techniques such as X-ray 
crystallography and NMR possess a lot of challenges and usually are not very informative about 
the native state of IDPs. 
     This project covers thorough studies of αSN’s structural and conformational dynamics in the 
presence of a phospholipid bilayer nanodisc using TRESI-HDX-MS. This powerful technique has 
the capabilities to probe the dynamics of non- to weakly structured regions of the protein on the 
millisecond to seconds time scale which will help to elucidate key transition intermediates in the 
folding/misfolding pathway of αSN during the interaction with lipid bilayer. Nanodisc technology 
will allow for “nature-like” environment during αSN - lipid interaction and, therefore, give more 
insights in possible αSN’s in vivo behavior.   
     We are certain that accurate determination and understanding of αSN’s structural dynamics 
in the presence of nanodisc phospholipid bilayer is a key step in designing a drug that can stabilize 
the native folded state of αSN and reduce its accumulation in the neuron’s cytosol.  
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Chapter 2: Experimental Methods 
2.1. Chemicals and Supplies 
     The chemicals used in this project were purchased from Sigma-Aldrich, Thermo-Fisher 
Scientific, BioBasic, and Avanti Lipids unless otherwise specified and were of ACS grade or higher. 
Ultrapure water was generated in-house by a Millipore Milli-Q Advantage A10 system. The E.coli 
BL21-CodonPlus(DE3)-RIPL competent cells were purchased from Agilent Technologies. Plasmids 
pET28a-MSP1D1, pET28a-MSP1D1∆H5, and pET28a-MSP1D1∆H4H5 were obtained through the 
collaboration with Audette Lab at York University. E.coli BL21 (DE3) containing SNCA in pet23a 
was kindly provided by Dr. Anurag Tandon’s lab at the Tanz Centre for Research in 
Neurodegenerative Diseases. Ni Sepharose 6 Fast Flow and Q-Sepharose Fast-Flow resin were 
bought from GE Healthcare. Bio-Beads SM-2 were purchased from Bio-Rad Laboratories. 
Spectra/Por dialysis membrane RC tubing with 6-8 MWCO was obtained from Spectrum Labs. 1D 
31P NMR was performed on a Bruker DRX 600 spectrometer with the XWIN-NMR software 
package. Size exclusion liquid chromatography (SEC) was carried out on the AKTA Purifier 10 (GE 
Helthcare) using a Tosoh Bioscience TSKgel column BioAssist G3SWXL (30cm x 7.8 mm ID, 5um) 
under the control of Unicorn 5.31 software package. The microfluidic channel design was 
generated using CorelDraw X3 (Corel, Ottawa, ON) and imprinted on VersaLaserTM engraver 
(Universal Laser, Scottsdale, AZ) Mass spectra were acquired on Synapt G1 and G2S high 
definition mass spectrometers from Waters under the control of MassLynx V 4.1 software 
package.  
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2.2. Expression and Protein Purification 
     2.2.1. E.coli DH5α containing Membrane Scaffold Protein (MSP) Variants 
     2.2.1.1 Transformation into E.coli BL21, Cell Growth and Expression of MSPs 
      E. coli (DE3) cells containing MSP1D1, MSP1D1 ∆H5, or MSP1D1 ∆H4H5 in pET28a were 
separately cultured overnight in 20 mL of Luria-Bertani (LB) medium containing 20 µM kanamycin 
(Kan) (50 mg /ml stock) and 200 µM of 1M glucose by shaking at 200 rpm at 37˚C. Cells were 
harvested for plasmid miniprep using Thermo Scientific GeneJET Plasmid Miniprep Kit. 
Transformation of the obtained plasmids was performed by mixing 200 ng of each plasmid with 
100 µL of ice-thawed E.coli BL21-CodonPlus(DE3)-RIPL competent cells and incubation of this 
mixture for 25 min on ice. Consequent heat shock at 42°C was applied for 90 sec, followed by 
incubation on ice for 5 minutes. Then 900 µL of LB broth was added to each mixture and 
incubation for 1 hour at 37°C and 125 rpm took place. 100 µL of each plasmid mixture was 
streaked on Kan LB plates. Plates were incubated at 37°C overnight. One cell colony was picked 
from each plate and introduced into 20 mL of LB with 20 µM Kan (50 mg/ml stock) and 200 µM 
of 1M glucose – these mixtures were incubated overnight at 37°C and 200 rpm. Glycerol stocks 
were made by mixing 500 µL of the overnight cultures with 500 µL 50% glycerol and stored at -
80°C. These transformed E. coli BL21-CodonPlus (DE3) cells containing pET28a-MSP1D1, pET28a-
MSP1D1∆H5, and pET28a-MSP1D1∆H4H5 plasmids were cultured overnight in 50 mL of LB 
containing 50 µM Kan (50 mg/ml stock) and 500 µM of 1M glucose overnight at 37°C and 200 
rpm. The overnight cultures were transferred into 500 mL LB-kanamycin medium (same 
concentrations as overnight medium) and grown to mid-log phase (OD600 0.6-0.8). The translation 
of these proteins was induced by adding 1mM final concentration of isopropyl β-D-1-
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thiogalactopyranoside (IPTG). After three hours of induction, the cells were harvested by 
centrifugation at 10,000 x g for 30 minutes at 4˚C. Cell pellets that were not used right away were 
stored at -20˚C for future use. 
 
 2.2.1.2. Ni2+ Affinity Purification of MSPs 
     Cell pellets were resuspended in 40 mL of 20 mM phosphate buffer pH 7.4, followed by adding 
a final concentration 1mM phenylmethylsulfonyl fluoride (PMSF), a final concentration of 1% 
Triton X-100, 2 mg of deoxyribonuclease I, and 0.8 mL of protease inhibitor cocktail (0.1M 
benzamide and 0.05M PMSF in 99% ethanol). Proteins were released from the cells by ultrasonic 
lysis with a sequence set to 6 minutes (15 seconds off, 15 seconds on) at 30% amplitude. The 
post-sonication solutions containing MSP1D1, MSP1D1 ∆H5 or MSP1D1 ∆H4H5 proteins were 
centrifuged at 30,000 × g for 30 min at 4°C. The resultant supernatants were collected and loaded 
on preequilibrated with Wash buffer 1 (40 mM Tris/HCl, 0.3 M NaCl, 1% Triton X-100, pH 8.0) 
immobilized Ni2+-affinity gravity chromatography columns. Subsequently, each column was 
washed with 250 mL of Wash buffer 1, 250 mL of Wash buffer 2 (40 mM Tris/HCl, 0.3 M NaCl, 50 
mM Na-cholate, 20 mM imidazole, pH 8.0), and 250 mL of Wash buffer 3 (40 mM Tris/HCl, 0.3 M 
NaCl, 50 mM imidazole, pH 8.0). Elution of each MSP protein was performed by washing the 
column with 150 mL of Elution buffer (40 mM Tris/HCl, 0.3 M NaCl, 0.4 M imidazole, pH 7). The 
first 10 fractions (approximately 5 mL each) of each purification were collected and visualized 
using sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE). Elutions containing 
MSP1D1, MSP1D1 ∆H5 or MSP1D1 ∆H4H5 proteins were collected and dialyzed into 20 mM 
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Tris/HCL, 0.1 M NaCl, 0.5 mM EDTA, pH 7.4. Dialysis experiments were performed by using 12-14 
kDa MWCO dialysis tubing membrane.  
 
     2.2.1.3 Protein Concentration and Storage  
     Concentration was verified by NanoDrop 2000 UV-Vis Spectrometer and Bradford Assay. 
Samples were concentrated using 10 kDa Vivaspin column if needed and stored in 20% glycerol 
at -80˚C. 
 
      2.2.2. E.coli BL21 containing SNCA in pet23a 
      2.2.2.1. Cell Growth and Expression of αSN 
     E. coli BL21 cells containing pET-23a vector encoding SNCA were cultured in 50 mL of LB 
medium containing 50 µM Kan (50 mg/ml stock) and 500 µM of 1M glucose overnight at 37°C 
and 200 rpm.  The overnight culture was transferred into 500 mL LB-kanamycin medium (same 
concentrations as overnight medium) and left growing overnight at 37°C and 200 rpm until mid-
log phase was reached (OD600 0.6-0.8). The translation of the protein was induced by adding 1mM 
final concentration of IPTG. After three hours of induction, the cells were harvested by 
centrifugation at 10,000 x g for 30 minutes at 4˚C. Cell pellets that were not used right away were 
stored at -20˚C for future use. 
 
     2.2.2.2. Protein Release by Cell Sonication and Boiling 
     For protein purification, cell pellets were resuspended in 25 mL of Suspension buffer 
(Phosphate Buffered Saline pH 7.2 (1xPBS) and 1mM PMSF.) αSN was released from the cells by 
ultrasonic lysis with a sequence set to 6 minutes (25 seconds off, 25 seconds on) at 18% 
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amplitude. Sonicated cells were transferred to a heat-resistant tube and boiled in a 100˚C water 
bath for 15 minutes. The sample was centrifuged at 10,000 x g for 15 minutes and the 
supernatant was collected. The resulting supernatant was spun again at 35,000 x g for 35 minutes 
and the final supernatant was collected for dialysis into 50mM Tris, pH 8.3. Protein purification 
must be performed on the day the last dialysis exchange is completed. 
 
     2.2.2.3. Protein Purification by Anion Exchange Chromatography 
     Purification of αSN was continued by performing anion-exchange chromatography using a Q-
Sepharose gravity column. The column was washed with 3 column volumes (CV) of 20% ethanol 
and 5 CV of 50mM Tris, pH 8.3 before loading dialyzed solution containing αSN. Elution of the 
protein was obtained by loading a step NaCl gradient – 100 mM, 150 mM, 200 mM, 250 mM, 300 
mM and 500mM at 50 mL each. All fractions were collected and visualized using SDS-PAGE. 
Elutions containing αSN were collected and dialyzed into 20mM Tris-Cl, pH 7.4. All dialysis 
experiments were performed using 6-8 kDa MWCO dialysis tubing membrane.  
 
     2.2.2.4 Protein Concentration and Storage 
     Concentration was verified using the Bovine Serum Albumin (BSA) assay. Samples were 
concentrated using a 3kDa Vivaspin column if needed and stored in 20% glycerol at -80˚C. 
 
2.3. Protein Visualization 
     As previously mentioned in sections 2.2.1.2 and 2.2.2.3, elutions from Ni2+-affinity and anion-
exchange gravity columns were collected and run in the 12.5% SDS-PAGE. 12.5% polyacrylamide 
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gels were made by first preparing separation gel where 6.93 mL ddH2O, 5.2 mL 40% acrylamide, 
4.2 mL 1.5M Tris pH 8.8, 166.5 µL 10% SDS, 166.5 µL 10% ammonium persulfate (APS), 16.5 µL  
tetramethyl ethylenediamine (TEMED) were mixed and loaded into four gel-casting chambers. 
After the waiting period of 20 min, stacking gel was made by mixing 3.16mL ddH2O, 0.5 mL 40% 
acrylamide, 1.265 mL 1 M Tris pH 6.8, 50 µL 10% SDS, 50µL 10% APS, 5 µL TEMED which was then 
loaded on top of separation gels. Gel electrophoresis was performed at 220V for 43 min on Bio-
Rad PowerPac basic power supply. Running buffer for gel electrophoresis was 1xTris-Glycine (25 
mM Tris-Cl, 250 mM glycine, 0.1% SDS). Afterwards, gels were stained for 20 min using  0.1% 
Coomassie Brilliant Blue R-250, 50% methanol and 10% glacial acetic acid buffer while gently 
shaking the gel’s container. Distaining was done by gently rocking the gel with 40% methanol and 
10% glacial acetic acid.  
 
2.4. Protein Desalting and Electrospray Ionization Mass Spectrometry (ESI-MS) 
     All proteins (αSN, MSP1D1, MSP1D1 ∆H5, and MSP1D1 ∆H4H5) were desalted and dialyzed 
against 50mM ammonium acetate pH 7.4 by Zeba Spin desalting columns (7K MWCO). The native 
spectra of αSN, MSP1D1, MSP1D1 ∆H5, and MSP1D1 ∆H4H5 proteins were obtained using a 
Waters Synapt G2-S Mass Spectrometer set to the positive mode. αSN was diluted to 2.5 µM in 
50mM ammonium acetate pH 7.4 and infused into the mass spectrometer at a flow rate of 5 
µL/min at 2.4 kV. Sampling cone was set to 50V, source temperature to 60˚C, desolvation 
temperature to 150˚C, trap collision energy to 4.0, transfer collision energy to 10.0, and trap gas 
flow to 2.00 mL/min. All MSPs were diluted to 1.5 µM in 50mM ammonium acetate pH 7.4 and 
infused into the MS at a flow rate of 5 µL/min at 2.0 kV. Sampling cone was set to 70V, source 
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temperature to 100˚C, desolvation temperature to 150˚C, trap collision energy to 15.0, transfer 
collision energy to 10.0, and trap gas flow to 2.00 mL/min.  
 
2.5. Nanodisc Assembly 
     The working lipid stock mixture was prepared by resuspending lyophilized 14:0 PC, also known 
as DMPC, with HPLC grade water for a final concentration of 50 mM producing the “lipid stock”. 
Equal amounts of lipid stock solution and 100mM Na-cholate (1:1 ratio) were mixed, then heated 
under ~50° tap water for 2-3 minutes and sonicated in an ultrasonic bath until the solution is 
clear and no lipid remains on the walls of the tube. This is the “working lipid stock” where the 
final concentration of Na-cholate is double that of DMPC. The optimum ratios for different sizes 
of nanodisc were taken from Table 1 which was adopted from Bayburt et al 103.   
Table 1. Optimum protein-lipid ratios for nanodisc formation for three different phosphatidyl-
cholines (PCs) and three different MSPs.1  
 Lipid Optimum ratios 
for MSP1 
MSP1ΔH5 MSP1ΔH4H
5 
Incubation 
temperature 
DPPC 90:1 56.3:1 22.5:1 37 ºC 
DMPC 80:1 50:1 20:1 25 ºC 
POPC 65:1 40.6:1 16.25:1 4 ºC 
                     1 Adapted from Bayburt et al, 2002 103. 
     Upon mixing the recommended ratios of DMPC lipids with MSPs, these nanodisc 
reconstruction mixtures were incubated for 15 minutes at 25˚C, then 1 hour at 4˚C. Next, 
BioBeads SM-2 in the amount of 0.6 g per 1 mL were added to the reconstruction mixture. These 
suspensions were then placed on an orbital shaker and incubated for at least 2 hours at 4°C. 
Formed nanodiscs were then removed from the beads with storage at 4°C for future use and 
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confirmed using NMR spectroscopy. The nanodiscs were further purified by SEC using 0.1M 
NH4OAc, pH 7 as elution buffer for future MS use. A different lipid constitution was also tried out 
– 80% DMPC and 20% 16:0-18:1 PS (POPS). All the steps in the formation of nanodiscs were the 
same. The general outline of the key steps in formation of nanodiscs is illustrated in Figure 15.  
Figure 15. Key steps in the formation of phospholipid nanodiscs. Starting from the top left, 
phospholipids are resuspended in aqueous solution by sonication and warm water. Then, 
detergent in the form of sodium cholate is added to the lipids. This stabilizes the lipids to form 
cholate-lipid micelles. If the lipid-detergent solution is not clear, lipids have precipitated into 
bulky lipid aggregates. Next, MSPs in cholate buffer and BioBeads SM-2 are added to the micelles.  
During incubation of this mixture, lipids start to replace the detergent that was bound to the 
protein, the detergent is adsorbed by the beads, and the nanodisc is formed.  
 
2.6. Verification of Nanodisc Formation by 1D 31P Nuclear Magnetic Resonance  
        (NMR) and Size Exclusion Chromatography (SEC) 
     Formed nanodiscs were spiked with 10% D2O and placed in a 5mm broad band NMR probe. 
1D 31P NMR experiments were recorded at 298K on a Bruker DRX 600 spectrometer. Each 
spectrum was recorded in 40,960 scans with a relaxation delay of 0.77 seconds at a frequency of 
242.9 MHz and 30˚ pulse angle. Spectra were processed with the XWIN-NMR software package.   
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Formed nanodiscs were also verified by SEC on the AKTA Purifier 10 (GE Healthcare) using Tosoh 
Bioscience TSKgel column BioAssist G3SWXL (30cm x 7.8 mm ID, 5µm,) with the separation range 
of 10 to 500 kDa under the control of Unicorn 5.31 software package. Nanodisc sample in the 
amount of 500 µL was first introduced in a pre-equilibrated 500 µL injection loop. Second, the 
column was equilibrated with 0.1 CV of 0.1 M ammonium acetate pH 7, followed by injection of 
the nanodisc sample into the column. This was followed by 1.5 CV elution at a flow rate of 0.5 
mL/min using 0.1 M ammonium acetate pH 7 and collection of samples at 0.5 mL each. The 
chromatogram was generated in Unicorn 5.31 software package with UV absorption readings at 
280 nm and 215 nm. 
 
2.7. Electrospray Ionization Mass Spectrometry (ESI-MS) of 6nm Nanodisc 
     The native MS spectra of MSP1D1 ∆H5 nanodisc (6 nm nanodisc) was obtained using a Waters 
Synapt G1 mass spectrometer set to the positive mode. After SEC purification, samples were 
dialyzed into 0.2 M ammonium acetate pH 7.4 and infused into the mass spectrometer at a flow 
rate of 15 µL/min and 2.5 kV. Sampling cone was set to 200 V, source temperature to 100˚C, 
desolvation temperature to 150˚C, trap collision energy to 30, transfer collision energy to 4, and 
trap gas flow to 2.50 mL/min. Backing pressure was set to 5.32 bar. 
 
2.8. Time-Resolved-Electrospray Ionization Mass Spectrometry (TRESI-MS) 
     The TRESI-HDX experiment begins with packing the proteolytic reaction chamber (Figure 16) 
with protease XIII agarose beads which were obtained by functionalizing protease XIII on agarose 
beads in 10% acetic acid (pH 2.3) overnight at 4˚C. Next, the TRESI apparatus was assembled 
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(highlighted in light-pink in Figure 16). The notch was cut 4 mm from the sealed end of glass 
capillary by VersaLaserTM laser engraver. Then, the TRESI apparatus and acetic acid line were 
connected to the mixing tee (grey circle in Figure 16) and, subsequently, connected to the 
microfluidic chip. All acid, protein, and deuterium syringes were attached to the corresponding 
capillary lines and placed on Harvard 11+ infusion syringe pumps (Holliston, MA). The principal 
of time-resolved HDX is shown in Figure 16 (enlarged pink portion of Figure 16), where protein 
flowing through the glass capillary exits into the outer metal capillary through a notch. Deuterium 
flowing in the outer metal capillary mixes with protein at the notch region which allows for 
millisecond to second deuterium exchange as the HDX reaction will be quenched by acid in the 
mixing tee. Quenched protein is then digested in the protease/pepsin reaction chamber and 
resulting peptides enter the mass spectrometer via ESI (Figure 16).  
Figure 16. Illustration of the experimental setup for a typical TRESI-HDX experiment. Starting 
from the pink inset, two syringes filled with D2O and protein are hooked up to a T-connector by 
glass capillaries. The third end of the T-connector is attached to a metal capillary (bigger in 
diameter than the glass one). The protein’s glass capillary is threaded trough the metal capillary, 
D2O directly flows inside the metal capillary. Protein and D2O meet and mix at the notch, which 
can be pulled back for varying volumes of the HDX reaction. This time-resolved mixer is then 
connected to a mixing tee (grey circle). The acid line is also attached to the tee where quenching 
of HDX occurs. The mixing tee is connected to the microfluidic chip filled with protease XIII. 
Vrxn 
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2.9. Microfluidic Device Fabrication 
     The microfluidic chip was made, first, by cutting a blank poly-methyl methacrylate (PMMA) 
block purchased from Professional Plastics (Fullerton, CA) into two rectangles (5 cm x 2 cm). Then, 
the pepsin/protease reaction chamber as well as “in” and “out” channels were engraved on one 
of the PMMA rectangles using a VersaLaserTM engraver (Universal Laser, Scottsdale, AZ). The 
microfluidic channel design was generated using CorelDraw X3 (Corel, Ottawa, ON). Back to the 
chip assembly, the engraved block was sandwiched with the blank PMMA and fused together 
using Weld-On 4 acrylic adhesive. The microfluidic chip was left to dry overnight. Treads for the 
wing nuts were made for the “in” and “out” channels using a 10/32 NF drill bit on the drill press 
station. The final product of the microfluidic chip device is shown in Figure 17. 
 
Figure 17. Microfluidic chip designed and produced by the Wilson Lab with its dimensions. 
 
2.10. Hydrogen/Deuterium Exchange of αSN and αSN-DMPC nanodisc (6nm) 
          complex; Equilibrium Studies 
    TRESI-HDX-MS equilibrium experiments included 6 time-points for two different protein states: 
αSN alone and αSN in complex with the 6nm DMPC nanodisc. Starting with sample preparation, 
the complex of αSN with the MSP1D1 ∆H5 DMPC nanodisc (6nm) was formed by mixing them 
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together at a 1:1 ratio. Both αSN and the MSP1D1 ∆H5 DMPC nanodisc were in their storage 
buffers prior to mixing (see sections 2.2.1.2 and 2.2.2.3). The mixture was incubated at 37°C for 
1 hour at 100rpm. Formed complex was verified and purified from unbound lipids and proteins 
by SEC using the same LC method and parameters from section 2.6. SEC fractions under UV280 
chromatographic peaks were also visualized using SDS-PAGE for confirmation of complex 
formation. SEC also served to desalt and buffer exchange the αSN - DMPC 6nm nanodisc complex 
into 0.1 M ammonium acetate pH 7. For αSN alone, desalting and buffer exchange into 0.1 M 
ammonium acetate pH 7 was performed using Zeba Spin desalting columns (7K MWCO). For both 
protein states, the TRESI-HDX-MS experimental set-up was the same. Flow rates were 5 µL/min 
for 10 µM αSN alone or 10 µM complex, 5 µL/min for D2O, and 20 µL/min for 10% acetic acid. 
Quenched samples were digested by protease XIII, and the resulting peptides were ionized by 
electrospray into the mass spectrometer. IMS was employed in the TriWave cell of the Synapt 
G2S to improve spatial resolution of peptides in the digested sample. Six time points (0.12 sec, 
0.34 sec, 0.66 sec, 1.32 sec, 2.2 sec and 3.3 sec) were obtained for each protein state. For each 
time point three technical replicates were acquired. Mass spectra of protease XIII equilibrated 
with 0.1 M ammonium acetate pH 7, HPLC water and 10% acetic acid was acquired (flow rates 
were 5 µL/min for buffer, 5 µL/min for water, and 20 µL/min for acid). In addition, a peptide 
digest acquisition of the 6nm DMPC nanodisc sample was obtained to exclude all the peptides 
coming from MSP1D1 ∆H5 (same flow rates as protease XIII control). Nanodiscs for this control 
were buffer exchanged into 0.1 M ammonium acetate pH 7 using SEC (see section 2.6). Both 
protein states were analyzed on the same day to exclude for possible day-to-day variability. 
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2.11. Hydrogen/Deuterium Exchange of αSN and αSN-DMPC nanodisc (6nm)  
           complex; Kinetic Studies 
     TRESI-HDX-MS kinetic experiments also included 6 time-point runs for two different protein 
states - αSN alone and αSN complexed with the MSP1D1 ∆H5 DMPC nanodisc. Starting with 
sample preparation, for αSN alone and αSN that will be mixed with nanodiscs, desalting and 
buffer exchange into 0.1 M ammonium acetate pH 7 using Zeba Spin desalting columns (7K 
MWCO) was performed. Nanodiscs were desalted and buffer exchanged into 0.1 M ammonium 
acetate pH 7 using SEC (see section 2.6). For both protein states, the experimental set-up was 
the same. For αSN alone, 5 µL/min of 10 µM αSN was flowing in the protein line, 5 µL/min D2O 
was flowing in the deuterium line, and 20 µL/min of 10% acetic acid in the acid line. For αSN 
mixing with the nanodisc state, 5 µL/min of 10 µM αSN was flowing in the protein line, 5 µL/min 
of D2O mixed with 10 µM 6nm DMPC nanodisc was flowing in the deuterium line, and 20 µL/min 
of 10% acetic acid in the acid line. Quenched samples were digested by protease XIII and resulting 
peptides were ionized by electrospray into the mass spectrometer. IMS was employed in the 
TriWave cell of the Synapt G2S to improve spatial resolution of peptides in the digested sample. 
Four or six time points (0.12 sec, 0.34 sec, 0.66 sec, 1.32 sec, 2.2 sec and 3.3 sec) were obtained 
for each protein state. For each time point three technical replicates were acquired. Mass spectra 
of protease XIII equilibrated with 0.1 M ammonium acetate pH 7, HPLC water and 10% acetic acid 
was acquired as a control (flow rates were 5 µL/min for buffer, 5 µL/min for water, and 20 µL/min 
for acid). Both protein states were analyzed on the same day to exclude for possible day-to-day 
variability. 
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2.12. Data Acquisition 
     TRESI-HDX-MS was performed on a Synapt G2S which consists of a StepWave ion guide, 
quadrupole, TriWave cell containing Trap, IMS and Transfer cells, and a TOF analyzer (Figure 18). 
For TRESI-HDX-MS experiments the following parameters were used: 2.5 kV capillary voltage, 
120°C source temperature, 25.0 sampling cone, 250 °C desolvation temperature, 50 L/hr cone 
gas flow, 6.0 Trap collision energy (CE), 6.0 Transfer CE and 90 mL/min IMS gas flow. Acquisition 
range was m/z 400 to 1500. TOF analyzer was in sensitivity mode. Ionization mode was ES+. 
Optimal positioning of the electrospray tip was achieved using an adjustable stage. 
Figure 18. Instrument schematic of a Synapt G2S (Waters, MA). Ions are introduced into the 
mass spectrometer through an ESI sources and selected through a StepWave ion guide and 
subsequent quadrupole.    
      
2.13. Data Analysis and Representation 
     The peptic digest of αSN was analyzed using FindPept tool on the ExPASy Proteomics server 
166. This software assigns resulting masses to possible peptides based on the sequence of the 
protein. If more than one peptide was matched to the same mass, MSMS was performed for 
peptide identity. A 1-hour protease XIII digest of αSN was subjected to LC-MSMS on an EASY-
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nLC™ nanoflow LC system (Thermo Fisher, MA) coupled with an LTQ Orbitrap Elite mass 
spectrometer (Thermo Scientific, MA). A 30 min gradient with 0.1% formic acid in water as the 
LC mobile phase A and 80% acetonitrile as the LC mobile phase B was implemented in this LC-
MSMS workflow. Resulting MSMS spectra were analyzed with Proteome Discoverer 1.4 software 
package . Identified peptides were analyzed for deuterium uptake using Mass Spec Studio 1.0 - a 
free software developed in Dr. David Schriemer’s research group 167. Deuterium uptake 
difference and kinetic plots were made using Excel software. Mapping of the deuterium uptake 
onto crystal structures of α-syn was performed using PyMOL software 168. 
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Chapter 3: Results and Discussion 
3.1. Purification of αSN and MSPs 
     3.1.1. SDS-PAGE of Samples Taken During Expression and Purification of MSP1D1, MSP1D1  
                ∆H5, and MSP1D1 ∆H4H5 
     All MSPs were expressed in E.coli BL21-CodonPlus(DE3)-RIPL competent cells for 3 hours at 
37°C. The expression trial for MSP1D1 is shown in the first five lanes of Figure 19 (excluding the 
MWM lane). According to literature the molecular weight of the MSP1D1 protein is 24.6 kDa, the 
gel band for which should be located very close to the 25 kDa mark 108.  
 
Figure 19. SDS-PAGE of expression and purification of MSP1D1. From left to right: molecular 
weight marker (ThermoFisher #PI-26616), MSP1D1 expression pellets from 0 to 3 hours at 37˚C, 
supernatant collected after pelleting the expressed cells, pellet and supernatant collected after 
lysis, fraction collected after supernatant was loaded on the column, fractions collected from 
subsequent wash of the beads with Wash buffer 1, 2 and 3, elutions 1 to 5 of MSP1D1 protein 
with Elution buffer. The thick bands in elution E1 to E4 at 25 kDa mark indicated the presence of 
purified MSP1D1 protein which has the theoretical mass of 24.6 kDa. These fractions were pooled 
and later used for 10 nm nanodisc formation. 
 
          During the expression there was an increase in thickness of the band corresponding to 
MSP1D1 at 2nd and 3rd hours of incubation. This result suggested the successful expression of 
the MSP1D1 protein.  To ensure that E.coli cells stayed intact during the pelleting step, the sample 
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of supernatant (S/N aft. pellet. in Figure 19) was run on the gel as well. During the purification 
process of MSP1D1, pellet (Pellet lysis in Figure 19) and supernatant (S/N lysis lane in Figure 19) 
after the sonicated debris was spun down were run in order to show that MSP1D1 was 
successfully released from the cells into a soluble fraction. Both of the lanes corresponding to 
these samples showed two bands at the 25 kDa mark with a similar thickness, proposing that 
some of the protein got precipitated along with the cell debris (Figure 19). The precipitation of 
MSP1D1 can be explained by binding of this MP to the membrane of E.coli cells and precipitating 
along with it. The supernatant containing solubilized MSP1D1 was loaded on a Ni2+ affinity gravity 
column and subsequent washes and elutions are shown in the last nine lanes of Figure 19. “Load” 
lane represents the flow-through after MSP1D1 was loaded onto the column. This lane contained 
various bands embodying a range of different sized proteins which did not bind to Ni2+ beads and 
eluted (Figure 19). No significantly thick band was observed at 25 kDa due to successful binding 
of MSP1D1 to Ni2+ beads by its 6xHis tag (Figure 19). Samples from the three washes of the Ni2+ 
column had some MSP1D1 being eluted, especially after “Wash 3” (Figure 19). However, elutions 
1 to 4 displayed the thickest bands at the 25 kDa mark, making the protein lost in “Wash 3” and 
“Load” insignificant. No other visible bands were presented in elutions 1 to 4 which indicated 
successful purification of MSP1D1 from other proteins (Figure 19).   
     MSP1D1 ∆H5 was also checked for successful expression and purification. According to 
literature the molecular weight of the MSP1D1 ∆H5 protein is 22.1 kDa 108. Samples 
corresponding to the pellet (Pellet lysis in Figure 20) and supernatant (S/N lysis lane in Figure 20) 
after the sonicated debris was spun down were run in the first two lanes. No thick band at around 
22.1 kDa was observed for the “Pellet lysis” lane suggesting that all of the MSP1D1 ∆H5 protein 
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is contained in the supernatant (Figure 20). Indeed, a very thick gel band in the “S/N lysis” lane 
supports this result.  
 
Figure 20. SDS-PAGE showing purification of MSP1D1 ∆H5. From left to right: pellet and 
supernatant collected after lysis, fraction collected after supernatant was loaded onto the 
column, fractions collected from subsequent wash of the beads with Wash buffer 1, 2 and 3, 
elutions 1 to 2 of MSP1D1 ∆H5 protein, molecular weight marker (ThermoFisher #PI-26616), 
elutions 3 to 8 of MSP1D1 ∆H5 protein with Elution buffer. The thick bands in elution E4 to E7 
just below 25 kDa mark indicated the presence of purified MSP1D1 ∆H5 protein which has the 
theoretical mass of 22.1 kDa. These fractions were pooled and used to form 6 nm nanodisc. 
 
     Protein supernatant was loaded on the Ni2+ affinity gravity column. “Load” lane showed a 
range of different proteins suggesting that most did not bind to the Ni2+ beads and eluted from 
the column right away (Figure 20). No significant band for MSP1D1 ∆H5 was spotted suggesting 
the successful binding event of this protein to the column. Subsequent “Wash 1” displayed a 
range of proteins, but no substantial bands below 25 kDa (Figure 20). However, the “Wash 2” 
sample exhibited quite a thick band corresponding to MSP1D1 ∆H5 along with some faint bands 
above 45 kDa (Figure 20). A relatively small amount of MSP1D1 ∆H5 eluted in “Wash 3”, but it 
could be neglected compared to the thickness of bands in elutions 5 and 6 (Figure 20).  E4 to E7 
also showed thick bands just below the 25 kDa mark and no other visible bands indicating a 
successful purification of MSP1D1 ∆H5 (Figure 20).  
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          In the case of MSP1D1 ∆H4H5, the protein expression level was checked at a 3-hour time 
point after inducing with IPTG and compared with the 0-hour time point – first two gel lanes in 
Figure 21. According to literature the molecular weight of the MSP1D1 ∆H4H5 protein is 19.2 kDa 
108.  The successful expression of MSP1D1 ∆H4H5 was confirmed by a much thicker band at 18.4 
kDa at “3hr IPTG” lane than the same band at “0 hr IPTG” (Figure 21). As expected, the “Load” 
lane in Figure 21 showed a variety of unbound proteins to the column but did not indicate any 
significant amounts of unbound MSP1D1 ∆H4H5 as no thick band around the 18.4 kDa mark was 
detected. Only “Wash 1” was performed for the MSP1D1 ∆H4H5 purification and the 
corresponding gel lane exhibited just two bands above the 18.4 kDa mark meaning no MSP1D1 
∆H4H5 was eluted during this wash (Figure 21). Although elutions 2, 7, 8, and 9 had thick bands 
corresponding to MSP1D1 ∆H4H5, they also contained a range of fainter bands (Figure 21). While 
the protein was not purified to the same extent as the other MSPs, it was still used for 4 nm 
DMPC nanodisc formation (sections 2.5 and 2.6). 
Figure 21. SDS-PAGE of expression and purification of MSP1D1 ∆H4H5. From left to right: 
MSP1D1 ∆H4H5 expression pellets at 3 and 0 hours at 37˚C, molecular weight marker 
(ThermoFisher #PI-26616), fraction collected after supernatant was loaded onto the column, 
fractions collected from elution with Wash buffer 1, elutions 1 to 9 of MSP1D1 ∆H4H5 protein 
with Elution buffer. The presence of relatively more thicker bands at 18.4 kDa mark in E7 to E9 
indicated the presence of purified MSP1D1 ∆H4H5 protein with molecular mass of 19.2 kDa.   
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     3.1.2. SDS-PAGE of Samples Taken During Expression and Purification of αSN 
     According to literature, the molecular weight of αSN is 14.6 kDa 169. During the purification 
process of αSN, samples of supernatant (S/N lane in Figure 22) and pellet (Pellet in Figure 22) 
after the sonication of cells were run on the gel to confirm αSN’s solubilization. There was no 
band corresponding to αSN in the “Pellet”, and a very thick band between 14.4 and 18.4 kDa in 
the “S/N” – this was an indication of successful lysis and high-yield solubilisation of αSN. The 
“S/N” was very clean and only low intensity protein bands were observed (Figure 22). This purity 
can be explained by the boiling step that took place after lysis – most of the other proteins 
degraded and precipitated in the pellet.  
Figure 22. SDS-PAGE of expression and purification of αSN. 20µL of each sample was mixed with 
10µL of 4XSDS loading dye and boiled for 5 minutes at 100˚C. 12µL of each mix was loaded onto 
a 12.5% SDS gel and run at 220V for 40 minutes. From left to right: molecular weight marker 
(ThermoFisher #PI-26616), supernatant collected after sonication, pellet collected after 
sonication, molecular weight marker (ThermoFisher #PI-26616), fraction collected after 
supernatant was loaded onto the column, fractions collected from elutions 1 to 11. 
 
     After the supernatant was loaded onto the anion-exchange gravity column, the subsequent 
fractions were taken – “Load” and E1 to E11 (Figure 22). The “Load” lane showed a range of 
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different proteins suggesting that most eluted right away, but no significant band for αSN was 
observed indicating a strong electrostatic interaction of αSN with anion resin (Figure 22). Elutions 
1 to 3 were collected using 150 mM NaCl which contained low concentrations of αSN as well as 
other proteins (Figure 22). Starting from E4 up to E11, the only observable band presented 
corresponds to αSN (Figure 22). The thickest αSN’s bands were obtained using 500 mM NaCl and 
were collected as the most concentrated samples for further dialysis and TRESI-HDX experiments 
(Figure 22). 
 
3.2. Determination of Protein Molecular Mass by ESI-MS 
     3.2.1. Native MS of MSP1D1, MSP1D1 ∆H5, and MSP1D1 ∆H4H5 
          ESI-MS spectra of intact/undigested MSPs were obtained in order to confirm the protein 
identity by mass, as well as, check for any impurities or degradation products. Figure 23 displays 
three native MS spectra for these three proteins along with screenshots of ESIprot Online 
calculation results. For MSP1D1, two peak distributions are observed: 1) lower m/z range where 
peaks represent an unfolded protein state, and 2) higher m/z range where peaks represent a 
folded protein state (Figure 23). Using m/z values of five consecutive peaks corresponding to the 
unfolded state, the exact mass of MSP1D1 was calculated using ESIprot software (Figure 23). The 
calculated mass was 24,781.6208 ± 0.77801 Da which was quite consistent with the theoretical 
mass of MSP1D1 based on its sequence (24,661.9 Da). The discrepancy between these two 
masses might arise from the fact that theoretical mass is calculated based on monoisotopic peak 
value, but experimental mass is based on a peak’s centroid.  
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Figure 23. The native mass spectra of MSP1D1, MSP1D1 ∆H5, and MSP1D1 ∆H4H5 proteins. All 
MSPs were diluted to 1.5 µM in 50mM ammonium acetate pH 7.4 and infused into the mass 
spectrometer at a flow rate of 5 µL/min. A cartoon schematic of each MSP is shown alongside its 
respective mass spectrum, with cylinders representing α-helices.    
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      Similarly, for MSP1D1 ∆H5 and MSP1D1 ∆H4H5, the native spectra exhibited two peak 
distribution patterns corresponding to folded and unfolded protein states (Figure 23). Calculated 
masses in ESIprot for MSP1D1 ∆H5 and MSP1D1 ∆H4H5 were 21521.3666 ± 0.2930 Da and 
18635.4218 ± 0.0367 Da, respectively. Theoretical weights for MSP1D1 ∆H5 is 22,105.7 Da and 
for MSP1D1 ∆H4H5 is 19220.51 Da – these values did not deviate excessively from experimental 
mass values. The spectra also confirmed that each MSP was purified with no obvious degradation 
protein products or impurities. 
 
    3.2.2. Native MS of αSN 
     The native mass spectrum of intact αSN was obtained in order to confirm the presence of this 
exact protein in solution and identify any truncation or degradation products that might be 
present in the sample. The theoretical mass of αSN (based on its sequence) is 14,460 Da.  
 
Figure 24. The native mass spectrum of αSN. αSN was diluted to 2.5 µM in 50mM ammonium 
acetate pH 7.4 and infused into the mass spectrometer at a flow rate of 5 µL/min. 
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     Looking at the spectrum in Figure 24, only the unfolded protein peak distribution pattern was 
observed which was expected due to the disordered character of this protein (no folded 
secondary structure). Consecutive m/z values were entered into ESIprot which gave a 
deconvoluted mass value of 14,459.6189 ± 0.4778 Da. This value matched the theoretical mass 
perfectly. The spectrum also confirmed that αSN was purified with no degradation/truncation 
protein products or impurities. 
 
3.3. Verification of Nanodisc Formation by NMR and SEC 
     3.3.1. 1D 31P NMR of DMPC Nanodiscs – 10nm with MSP1D1 Belt, 6nm and 4nm with    
                MSP1D1 ∆H5 and MSP1D1 ∆H4H5 Belts, Respectively    
      Since many studies have been done on nanodiscs with NMR in the last 10 years, this technique 
was chosen to verify the three differently sized nanodiscs – 10 nm with MSP1D1 belt, 6 nm and 
4 nm with MSP1D1 ∆H5 and MSP1D1 ∆H4H5 belts, accordingly. 31P is a hundred percent naturally 
abundant isotope which makes it much more sensitive than 13C in NMR. Also, all lipids including 
DMPC have at least one phosphorous atom.  Therefore, 1D 31P NMR was chosen here as the best 
suited experiment. Figure 25 shows the NMR spectra for 10, 8 and 6 nm DMPC nanodiscs (from 
top to bottom), as well as a control sample of just DMPC lipid at the same concentration as in the 
nanodisc samples. The top three NMR spectra displayed a tall, sharp peak at around 0 ppm 
(Figure 25). In comparison, the bottom spectra of lipid control exhibited an almost unresolvable 
broad peak at around -15 ppm (Figure 25d ). The sharpness of a peak in 1D NMR is reversely 
proportional to the transverse relaxation time (T2), and T2 is directly proportional to correlation 
time of the molecule (Ϯc) which is simply how many revolutions a molecule undergoes in one 
second in solution. If the molecule is bulky then Ϯc is small – not many revolutions occur in 1 s. 
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Figure 25. 1D 31P NMR of DMPC nanodisc with a) MSP1D1 belt, b) MSP1D1 ∆H5 belt, and c) 
MSP1D1 ∆H4H5 belt, as well as, d) DMPC lipid aggregate. 1mM of DMPC diluted in 100 mM 
ammonium acetate with 10% D2O contained each sample of nanodiscs prior to 31P NMR 
experiments. These experiments were recorded at 298K on a Bruker DRX 600 spectrometer. Each 
spectrum was recorded in 40,960 scans with a relaxation delay of 0.77 seconds at a frequency of 
242.9 MHz and 30˚ pulse angle. Spectra were processed with the XWIN-NMR software package.     
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     In the bottom spectra, T2 is short which makes the peak broader. Therefore, broadening of 
the peak in the lipid control sample suggests the presence of a much bulkier substance than a 
formed nanodisc – possibly a lipid aggregate. This is consistent with the fact that lipids in a water-
based solution tend to form globular aggregates, so that lipid hydrophobic tails are buried from 
the hydrophilic environment. These DMPC aggerates will have small Ϯc and short T2 leading to 
formation of a broad peak (Figure 25d ). Similar results were also observed in the 1D 31P NMR 
studies by Lucyanna and colleagues in 2011 170. In their work, they also observed a broad peak at 
around −15 ppm which corresponded to the transition from bicellar aggregates to larger 
structures with slower motions – lipid aggregates 170.  In contrast, nanodiscs are much smaller 
and compact structures than lipid aggregates and rotated with larger correlation times, which 
made T2 long, producing sharp peaks (Figure 25 a, b, and c). Based on the results in Figure 25, 
the successful formation of all three (10, 8 and 6 nm) DMPC nanodiscs was established. 
 
     3.3.1. SEC and SDS-PAGE of 6 nm DMPC Nanodisc 
     Many nanodisc protocols have employed SEC for confirmation of nanodisc formation. 
Additionally, SEC is an excellent technique for dialysis of a sample into a MS compatible buffer 
while separating the nanodiscs from unbounded lipids, detergents and proteins. The SEC 
chromatogram for the 6 nm DMPC nanodisc (MSP1D1 ∆H5 belt) is shown in Figure 26 along with 
a SDS-PAGE gel depicting elution samples under representative chromatographic peaks. The blue 
peak trace represents the UV absorbance of aromatic amino acids (Phe, Tyr, Trp) at 280 nm from 
the MSP1D1 ∆H5 belt (Figure 26). The chromatogram has two main peaks: the first one eluting 
at 8 to 10 mL (elutions B8 to B5), and the second one at 13 mL (elution C1) (Figure 26).  
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Figure 26. Size exclusion chromatogram of the 6nm DMPC nanodisc (MSP1D1 ∆H5 belt) with 
the corresponding SDS-PAGE of the main peak elutions. The blue peak trace in the 
chromatogram corresponds to UV absorbance at 280 nm. SDS-PAGE displays (from left to right) 
molecular weight marker (ThermoFisher #PI-26616), nanodisc sample before SEC, elutions B8 to 
B6 and C1. 
 
  
         Given that larger molecular weight species elute earlier, the first peak was assigned to 
correspond to a much heavier species than the second peak. According to SDS-PAGE, elutions 
under the first peak (B8 to B5) displayed only one band below the 25 kDa mark which was 
assigned to the MSP1D1 ∆H5 protein (molecular mass 22.2 kDa) (Figure 26). Hence, the first 
chromatographic peak corresponds to the 6 nm DMPC nanodisc. This deduction was also 
supported by various literature results. For example, Hagn et al. have shown that a single SEC 
peak at 14.3 mL corresponds to the 95kDa DMPC nanodisc with MSP1D1 ∆H5 belt (column used 
in their research was analogous to the TSKgel column BioAssist G3SWXL column and the flow rate 
ǀ 
ǀǀ 
Peak I Peak II 
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was identical to the one used in this study) 108. Even though 14.3 mL corresponds more to the 
elution of the second peak in Figure 26, the discrepancy can be explained by different 
chromatographic properties of the column used by Hagn et al 108. Another research paper by 
Helbing et al. has confirmed the MSP1D1:DOPC nanodisc through an elution peak at 18 min using 
the same column and flow rate as in this study 171. Fraction B7 under the first peak in Figure 26 
eluted at 18 min. Both Figure 26 and reported literature results support the successful formation 
and purification of the 6 nm DMPC nanodisc (MSP1D1 ∆H5 belt). The fraction under the second 
peak showed no protein bands (Figure 26). This likely corresponds to the elution of small peptide 
fragments and any excess MSP1D1 ∆H5 that was not associated with the 6 nm nanodisc. 
 
3.4. Verification of αSN – 6 nm DMPC Nanodisc Complex by SEC, SDS-PAGE and 
        ESI-MS 
     Protein-nanodisc complex was formed by mixing the DMPC nanodisc (MSP1D1 ∆H5 belt) with 
αSN at a 1:1 ratio and left incubating for 1 hour at 37°C with shaking at 100 rpm. The SEC 
experiment was performed in order to confirm complex formation, transfer the sample into an 
MS compatible buffer and purify it from any unbound material like lipids, detergents and 
proteins. The corresponding chromatogram and SDS-PAGE gel containing representative elution 
samples are shown in Figure 27. The blue peak trace represents UV absorbance of aromatic 
amino acids (Phe, Tyr, Trp) at 280 nm from the MSP1D1 ∆H5 belt and αSN (Figure 27). Similar to 
the SEC chromatogram of empty nanodiscs (Figure 26), the chromatogram in Figure 27 had two 
main peaks: the first one at 8-10 mL with fractions B7 to B5, and the second one at 11-13 mL with 
fractions B2 to C1. However, the intensities of the peaks are different, with the second peak 
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having a higher intensity than the first (Figure 27), signifying that smaller molecular weight 
species was present at a higher concentration or had more aromatic amino acid residues present.  
 
Figure 27. Size exclusion chromatogram of αSN - 6nm DMPC nanodisc complex with the 
corresponding SDS-PAGE of the main peak elutions. The blue peak trace in the chromatogram 
corresponds to UV absorbance at 280 nm. SDS-PAGE displays (from left to right) molecular weight 
marker (ThermoFisher #PI-26616), αSN before complex formation, nanodisc sample before 
complex formation, complex of αSN with nanodisc (1:1) before SEC, elutions B8 to B5 and B1.  
 
     SDS-PAGE was used to visualize the species eluted in these two peaks (Figure 27). An αSN 
sample prior to complex formation (2nd lane with a thick band between 18.4 and 14.4 kDa marks 
in Figure 27) and a nanodisc sample (3rd lane with a thick band just below the 25kDa mark) 
confirmed purity of the samples prior to complex formation (Figure 27). The formed complex 
before SEC is shown in the 4th lane to make sure that both αSN and MSP1D1 ∆H5 belt did not 
degrade during the incubation time (Figure 27). Two thick bands in the 5th lane corresponding to 
these proteins confirmed their presence and intactness (Figure 27). Elutions matching the first 
ǀ 
ǀǀ 
Peak I Peak II 
63 
 
chromatographic peak (B8, B7, B6 and B5) also contain two bands corresponding to αSN and 
MSP1D1 ∆H5 (Figure 27). This result suggests that fractions under the first peak contained the 
protein-nanodisc complex. The drop in concentration of B8-B5 protein bands was due to the 
dilution of the complex sample into four fractions (Figure 27). It is to be noted that B8 showed a 
thin but distinguishable band only for MSP1D1 ∆H5 and that the concentration of αSN was either 
too low to visualize or not present (Figure 27). Since the empty nanodisc in Figure 26 had eluted 
at the same volume and retention time as the complex in Figure 27, it is reasonable to propose 
that elution B8 corresponds to an empty nanodisc (as in Figure 26), with all downstream elutions 
starting to contain the complex sample (Figure 27). It was unexpected to observe no shift 
between the first peaks in Figure 26 and 27, as nanodiscs bound with αSN should elute earlier by 
means of being a heavier species. However, it is hypothesized that αSN can stabilize the nanodisc 
complex and make it more compact which would lead to a later than expected elution time. This 
argument is supported by evidence that αSN’s binding to a lipid bilayer affects not only the 
properties of the protein but also the properties of the membrane (membrane remodeling, 
thinning and/or expansion) 172. For example,  Braun et al. on the basis of fluorescence correlation 
spectroscopy and POPG vesicle clearance assays had deducted that the NAC region of αSN was 
essential in stabilizing protein-lipid complexes and, in doing so, promotes the organization of the 
bilayer surface 173.  
     Solely relying on the SDS-PAGE results under the first peak in Figure 27, formation of the αSN 
– 6nm DMPC nanodisc complex was confirmed. As in Figure 26, the B1 fraction contained no 
proteins but was composed of small molecular weight peptides which was verified by using ESI-
MS (results not shown). 
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      Intact mass spectra of the 6nm DMPC nanodisc and complex of αSN - 6nm DMPC nanodisc 
were performed in order to confirm their masses. Mass spectra for both of these samples are 
shown in Figure 28. Both spectra displayed a broad peak distribution pattern looking almost like 
a “hump” – the top hump with a centroid around m/z 6000, and the bottom around m/z 5000. 
Unfortunately, the peak resolution of these two “humps” was too low for charge states to be 
identified, and, therefore, no deconvoluted mass was obtained (Figure 28). However, a 
comparison between the relative position of the centroids of these envelopes was performed.  
Figure 28. Mass spectra of a) intact 6nm DMPC nanodisc, and b) intact complex of αSN - 6nm 
DMPC nanodisc. Purple and green dotted lines represent the approximated centroids for each 
spectra. Data was obtained using a Waters Synapt G1 instrument with increased backing pressure 
to 5.32 bar. 
 
     The nanodisc centroid was approximated to be around m/z 5880 which is about 920 m/z 
higher than the approximated centroid for the complex (Figure 28). Even though the complex 
was expected to be heavier, it seemed to pick up more charge due to αSN’s polar and positively 
charged (Lys) residues on the surface of the nanodisc. These additional charges could have 
caused the overall shift to a lower m/z range. To conclude, no deconvoluted masses of both 6 nm 
DMPC nanodisc or complex was obtained, so the MS identity of these two samples was failed to 
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be confirmed. However, the difference in mass spectra shape could be used as a guidance for 
differentiation of one sample from another (assuming future replicates of this experiment would 
be consistent). 
 
3.5. Conformational Analysis of αSN When Bound to 6 nm DMPC Nanodisc;  
        Equilibrium Studies 
          To obtain peptide specific insights into the interactions of αSN with the 6nm DMPC 
nanodisc, equilibrium TRESI-HDX-MS studies were performed. Figure 29 shows equilibrium data 
in the form of deuterium uptake difference plots and corresponding heat-mapped 3D protein 
structures of αSN on the nanodisc. Difference plots of two technical replicates have αSN’s 
peptides in the order from N- to C-terminus on the x-axis, and percentage difference of 
deuterium uptake between complex and αSN alone (deuterium uptake of complex – deuterium 
uptake of αSN = ∆D uptake) on the y-axis (Figure 29). Heat-mapped 3D protein structures 
correspond only to the second replicate where red corresponds to an increase in deuterium 
uptake and blue to a decrease (Figure 29). Dotted red and blue lines represent two standard 
deviation values for each peptide. 
     In the earlier time points – 0.115 s and 0.332 s in the 2nd replicate and 0.38 s in the 1st replicate, 
the difference in deuterium uptake generally decreases (Figure 29). The three distinct peptide 
regions of αSN showing the most drastic decreases are AEKTKQGVAE (residues 19-28), 
VTNVGGAVVTGVTAVAQK (63-80), and TVEGAGSIAAATGFVKK (81-97) (Figure 29). 
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Figure 29. Two technical replicates of deuterium uptake difference plots between complex and 
αSN alone; equilibrium studies. The first replicate data is displayed in small boxes beside the 
second replicate data. The significant differences in deuterium uptake are mapped onto the 
structure of αSN (PDB ID:1XQ8), where blue color represents a decrease in deuterium uptake, 
and red an increase. 
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     AEKTKQGVAE showed a decrease of about 7% at 0.115 s and 0.38 s (2nd and 1st replicate 
accordingly), but at 0.332 sec in the 2nd replicate was below the two standard deviations value 
and displayed a difference of about -3%. VTNVGGAVVTGVTAVAQK displayed the greatest 
decrease among the three regions – around -15% at 0.115 s (2nd rep), -10% at 0.38 sec (1st rep) 
and -5% at 0.332 s (2nd rep) (Figure 29). TVEGAGSIAAATGFVKK had a similar behaviour – around 
-13% at 0.115 s (2nd rep), -7% at 0.38 sec (1st rep) and -6% at 0.332 s (2nd rep) (Figure 29). These 
results indicate that when αSN was in a complex with the nanodisc, deuterium uptake of amide 
hydrogens decreased compared to free αSN. As mentioned in section 1.1.2.1, the HDX rate is 
highly dependent on hydrogen bonding and solvent accessibility, and deuterium exchange is 
slower in folded proteins which are characterized by extensive hydrogen bonding networks and 
restricted solvent accessibility. Therefore, our data suggests that the conformation of αSN was 
changed when complexed to nanodiscs toward a more dynamically restricted form with a slower 
deuterium uptake. In particular, peptides belonging to the NAC region (residues 63-80, 66-80, 69-
80, 81-97 and 84-97) displayed the greatest protection from deuterium in the αSN-nanodisc 
complex which suggests that this is the specific interaction region with the lipid bilayer. In longer 
time points – 0.659 s in the 2nd replicate and 0.88 s in the 1st replicate, the difference in deuterium 
uptake still decrease or do not show any significant difference (Figure 29). Here, the longer time 
point from the second replicate did not change significantly from the 0.322 s or 0.38 s difference 
plots (Figure 29). The 0.88 s plot did not show any significant difference in deuterium uptake 
signifying no change in αSN’s structural dynamics upon interaction with lipids. The longest time 
points, 1.31 s and 1.63 s (2nd and 1st replicate accordingly) showed increases in the difference in 
deuterium uptake (Figure 29). Except for AEKTKQGVAE (residues 19-28), peptides from the NAC 
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region and C-terminus tail showed higher deuterium uptake (5-10%) compared to peptides in 
free αSN. 
     The transition from a decrease to increase in deuterium uptake during longer time points was 
an unexpected result. If αSN was bound to nanodiscs, decreases in deuterium uptake were 
expected to become even more prominent. The results in Figure 29 could be justified by another 
model – that αSN exhibits transient interactions with the 6 nm DMPC nanodiscs. In the 
equilibrium study there are different populations of αSN that may form, for example, αSN bound 
to the nanodisc, αSN that partially interacts with the nanodisc, and completely unbound αSN. 
The interchange of αSN between these populations may occur making one population more 
dominant over the other. It seems that under 0.659 s the dominant population is where αSN is 
conformationally restricted or more structured than free αSN (either bound αSN to nanodiscs or 
transiently interacting with them). Therefore, the HDX “snapshot” of earlier time points show 
decreases in deuterium uptake. However, at the 1.63 s reaction time, the transition of αSN from 
a conformationally restricted state to a more extended structure takes place leading to 
domination of an extended (and possibly more amyloidogenic) αSN population. Therefore, the 
HDX “snapshot” of the longer time points show increases in deuterium uptake. Unfortunately, 
no third technical replicate was obtained to make any statistical conclusions regarding this 
model. This consistency issue was addressed by running HDX-MS experiments on free αSN and 
complex on the same day. In addition, complex preparation and SEC clean-up was performed on 
the same day as the HDX-MS experiment. Last but not least, the pH reading of the quenched 
peptide solution was taken after each time point in order to avoid back-exchange (loss of 
deuterium label) and ensure successful quenching. Figure 30 shows the percentage of deuterium 
69 
 
uptake for αSN peptides (free protein, no nanodiscs present) at four randomly selected days, 
yielding highly consistent data.   
  
Figure 30. Deuterium uptake for free αSN on four randomly selected days. Percentage of 
deuterium uptake for each peptide is represented as a colored dot where each color belongs to 
one of the four days – 10Feb2018 dark red, 08Feb2018 violet, 11Dec2017 yellow, and 14Oct2017 
brown. 
 
     Peptides from NAC region of αSN exhibited very consistent percentage for deuterium uptake 
in all time points for all four different dates (Figure 30). The only outstanding values were 
exhibited by the NAC region peptides at 1.3 s on 14OCT (brown), but the overall line trend was 
very similar to the three other dates (Figure 30). Parallel to the NAC region peptides, C-terminus 
peptides and AEKTKQGVAE showed little deviation from date-to-date and the overall line trend 
for all four dates were the same (Figure 30). The most differences between different dates were 
observed in peptide YVGSK (resi 39-43) which locates at the isthmus between two α-helices in 
αSN. Due to its position in αSN, YVGSK was expected to exhibit various HDX rates due to the steric 
effects of nearby amino acid groups composing αSN’s helices. Therefore, it was proposed that 
0.115 sec 
0.659 sec 
0.332 sec 
1.3 sec 
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variety of conformational ensembles that YVGSK peptide may adapt influenced HDX rate and 
deuterium uptake profile (Figure 30). It is important to note that YVGSK is a very short peptide 
with only three deuterium exchange sites – this limited amount of exchange sites could also 
contribute to such date-to-date variability (Figure 30). Overall, it can be stated that free αSN’s 
deuterium uptake was consistent in all four randomly selected days in Figure 30. Consequently, 
the most variability and inconsistency in deuterium uptake results came from the αSN-nanodisc 
complex which led to inconsistencies in difference plots between the complex and αSN. 
     To conclude, on the basis of equilibrium TRESI-HDX-MS data, αSN was proposed to exhibit 
transient interactions with lipid bilayer of the 6 nm DMPC nanodisc. The third technical replicate 
supporting this deduction was not obtained due to the inconsistencies in the subsequent 
acquired data sets. Based on Figure 30 results, it was determined that inconsistencies came from 
the αSN-nanodisc complex HDX profiles indicating an erratic and infrequent structural behaviour 
of αSN in the presence of DMPC bilayer. The deduction of transient interaction rather than stable 
binding of αSN to DMPC nanodisc was backed up by the recent study of Viennet et al. where 
TROSI-HSQC NMR proved no binding of αSN to DMPC nanodisc as no differences to the spectrum 
of αSN in the presence/absence of nanodiscs was detected 173.  
 
3.6. Conformational Analysis of αSN During the Binding Event to 6 nm DMPC and  
        DMPC-POPS Nanodisc; Kinetic Studies 
     Kinetic studies were performed in order to elucidate the folding pathway of αSN into an α-
helix upon binding to the phospholipid bilayer of the 6 nm DMPC and DMPC-POPS nanodisc. The 
lipid-binding regions of αSN have been known for a while, but the peptides involved in early-on 
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launching on the membrane and transition folding states of αSN are not know yet 125,141,160. It is 
important to note the difference between kinetic experiments in this section from equilibrium 
studies in section 3.4. In equilibrium studies, complex of αSN and the 6 nm DMPC nanodisc was 
pre-made and all structural transitions of αSN linked to the interaction with lipids bilayer took 
place before the HDX reaction. In contrast, kinetic studies involved hydrogen exchange while the 
complex was forming, meaning αSN meets up nanodiscs only in the HDX reaction chamber. 
Therefore, kinetic studies allows for probing the dynamics of weakly structured regions of αSN 
during the first moments of the interaction with the nanodisc bilayer. The results of kinetic TRESI-
HDX-MS experiment were represented in Figure 31 in the form of deuterium uptake difference 
plots between the forming complex and αSN alone (deuterium uptake of forming complex – 
deuterium uptake of αSN = ∆D uptake). The correlated PyMOL structures of αSN with mapped 
difference in deuterium uptake were also presented in Figure 31 for better visualization of the 
regions most involved in structural changes.       
     Overall, kinetic data displayed the decrease in deuterium uptake across all time points, 
indicating a more dynamically-rigid structure of αSN in the presence of the 6 nm DMPC nanodiscs 
(Figure 31). The highest decreases in deuterium uptake were exhibited by the first two peptides 
AEKTKQGVAE   (19-28) and YVGSK (39-43) – around -20% at 0.12 s and 0.33 s, and around -10% 
to -14% at 0.66 s and 1.31 s. AEKTKQGVAE and YVGSK belong to the αSN’s amphipathic region 
which exploits the highest propensity of forming amphipathic helices, especially in the presence 
of lipid membranes 125,146. These two peptides were proposed to be the first ones in αSN’s 
sequence to start conformational changes in the presence of the lipid bilayer, presumably there 
are also the first ones to initiate folding process of αSN into the extended helical state.  
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Figure 31. Deuterium uptake difference plot between αSN – 6 nm DMPC nanodisc complex and 
αSN alone: kinetic studies. The deuterium uptake mapped onto the structure of αSN (PDB 
ID:1XQ8), where purple represents -20 to -15 percent decrease in D2O uptake, blue indicates -15 
to -10 per cent, and green -10 to -5. 
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    Unfortunately, this deduction cannot be fully evidenced unless all the peptides in amphipathic 
region are analyzed. Nevertheless, this data was partially supported by the findings of Bartels and 
his colleagues –the first 20 amino acids of amphipathic region were the earliest to transition into 
helical form pulling the rest of the lipid-binding region to undergo a coil/helix transition 78.  
     Peptides from the hydrophobic region of αSN (residues 63 to 97) showed lower deuterium 
uptake than the amphipathic region across all four time points: -15 to -10 % at 0.12 sec, and -10 
to -5 % at 0.33 s, 0.66 s and 1.31 s (Figure 31). But the decrease in deuterium uptake still indicated 
that the HDX rate got slower in αSN when introduced to the nanodisc, possibly due to the newly 
formed hydrogen bonding and restricted solvent accessibility. This result suggested a more 
structured conformation of the NAC region compared to the intrinsically disordered αSN. Since 
the NAC region only follows the coil/helix transition after the amphipathic region, the lower 
intensity in deuterium uptake compared to the first two peptides in Figure 31 was expected. Also, 
according to Dikiy et al. second helix of αSN (attributed to the NAC region) was proposed to kick 
itself out with the help of C-terminus in order to obtain the partially helical intermediate state 
(Figure 14), meaning this region is less stabilized by the membrane bilayer and more structurally 
dynamic. This could also explain the higher level of deuterium uptake by the NAC region in the 
αSN - DMPC nanodiscs forming complex compared to AEKTKQGVAE and YVGSK peptides in the 
same sample. 
     The C-terminus peptides QLGKNEEGAPQE (99-110) and EDMPVDPDNEAYE (114-126) also 
exhibited substantial decrease in deuterium uptake in the earlier time points (0.12 s and 0.33 s) 
– up to -16% and -11% for QLGKNEEGAPQE, as well as, -13% and -10% for EDMPVDPDNEAYE 
(Figure 31). However, in later time points EDMPVDPDNEAYE (114-126) showed no significant 
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difference indicating the same structural behaviour as in free αSN. The decrease in deuterium 
uptake for QLGKNEEGAPQE (99-110) got lowered to around -10% (Figure 31). As mentioned 
earlier, the C-terminus of αSN usually remains unstructured and either works as a protein-protein 
interaction motif or provides long-range interactions for stabilization of NAC and N-terminus 
regions 125,156,157. The data for the C-terminus peptides was conflicting, as no significant change 
was expected. But the lower deuterium uptake in this region clearly indicated structural rigidity 
and compactness of the C-terminus when introduced to the 6 nm DMPC nanodisc. The possible 
explanation was that the C-terminus region assisted in the reduction of αSN’s disordered 
character towards a folded species through interaction with either other regions of αSN, or 
nanodisc. This explanation could not be proved by the kinetic data nor backed up by any scientific 
literature.  
     In addition to the kinetic studies with DMPC nanodiscs, similar studies were performed with 
the 6 nm DMPC-POPS nanodiscs. POPS lipids have negatively charged polar heads that can 
contribute to the increased binding ability of αSN to the vesicle’s membrane 154,173. Kinetic plots 
for the seven peptides covering the three major parts of αSN were shown in Figure 32 (Part 1 and 
2). The x-axis represented six time points at which deuterium uptake measurements were 
acquired. The y-axis represented percentage of deuterium uptake at each time point starting 
from 60%. The 0 s time point was not measured and, therefore, omitted in the kinetics plots 
represented in Figure 32, Part 1 and 2. Two technical replicates were shown in Figure 32, Part 1 
and 2, where the second replicate kinetic plots were slightly shaded for visual distinction between 
the two sets of the HDX results. 
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Figure 32. Part 1. Kinetic plots for αSN alone (orange line) and αSN exposed to 6nm DMPC-
POPS nanodisc (turquoise line) during the kinetic studies.  
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Figure 32. Part 2. Kinetic plots for αSN alone (orange line) and αSN exposed to 6nm DMPC-
POPS nanodisc (turquoise line) during the kinetic studies experiment. 
 
     Analyzing Figure 32, Part 1 peptides from the amphipathic region of αSN, AEKTKQGVAE (19-
28) and YVGSK (39-43), showed the highest difference in deuterium uptake between the αSN-
nanodisc forming complex and the free αSN. This data agrees with the results obtained in Figure 
31, except that deuterium uptake was within -10% for the both replicates in Figure 32, Part 1.  
The decrease in deuterium uptake for these two peptides supported the previous conclusion of 
initiating the folding process of αSN into an extended helix. Negatively charged POPS lipids did 
not increase the binding capacities of αSN to the nanodisc bilayer, but rather reduced it.  
     The NAC region peptides VTNVGGAVVTGVTAVAQK (63-80) and TVEGAGSIAAATGFVKK (81-97) 
gave similar results in both replicates for the early time points (0.12s, 0.33 s and 0.66 s) – 
deuterium uptake for free αSN and the αSN-nanodisc forming complex was almost the same 
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(Figure 32, Part 1). This data suggested that no lipid-protein interaction or folding of this region 
into a more structurally rigid state occurred. The longer time points (1.3 s, 2.3 s, and 3.2 s) 
displayed different results for different replicates. In the 1st replicate, deuterium uptake for the 
αSN-nanodisc complex exhibited decreases starting from 4-5% to ~8% (Figure 32, Part 1). No 
differences were present in the 2nd replicate (Figure 32, Part 1). Third replicate is needed in order 
to confidently interpret αSN’s structural behaviour past 1.3 s. The HDX profiles for the NAC region 
peptides in Figure 32, Part  1 were quite dissimilar to Figure 31 results. Once more, the presence 
of 20% POPS lipids in the nanodiscs seemed to have no affect on binding properties of αSN to the 
membrane bilayer. Overall, NAC region displayed no signs of a protein-lipid interaction in kinetic 
studies with the 6 nm DMPC-POPS nanodiscs. 
     Kinetic plots for peptides in the C-terminus region, EDMPVDPDNEAYE (114-126) and 
QLGKNEEGAPQE (99-110) were represented in Figure 32, Part 2. The deuterium uptake results 
for EDMPVDPDNEAYE (114-126) demonstrated substantial error values for most of the time 
points, therefore, no clear result interpretation could be made (Figure 32, Part 1). However, this 
infrequent deuterium uptake may refer to the disordered behaviour of C-terminus region which 
obtains ensemble of conformational states with different HDX profiles. QLGKNEEGAPQE (99-110)  
displayed lower deuterium uptake after 0.66 s in both replicates for the αSN–nanodisc forming 
complex. Opposite results were observed before 0.66 s where the 1st replicate exhibited the 
higher deuterium uptake for the complex sample, and the 2nd replicate even a bigger decrease 
than after 0.66s (Figure 32, Part 1). The third replicate is needed to make any constructive 
observation about the C-terminus structural behaviour when αSN introduced to the DMPC-POPS 
nanodiscs.  
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     Before any final conclusions were made about the kinetic studies results, the comparison of 
the three replicate data sets was analyzed in the form of summed difference plots in Figure 33. 
The differences in deuterium uptake were summed across all acquired time points for: A) 1st 
replicate corresponding to the HDX studies of αSN - 6 nm DMPC nanodisc complex (Figure 31), 
B) and C)  1st and 2nd replicates corresponding to the HDX studies of αSN - 6 nm DMPC-POPS 
nanodisc complex (Figure 32), respectively. 
     For all three plots in Figure 33, the most common feature was a substantial decrease in the 
deuterium uptake for peptides in the amphipathic region of αSN (amino acids 12 to 43). The 
TRESI-HDX-MS results here supported that the most structural folding occurred in the peptide 
19-28, as it showed the highest decrease in deuterium uptake (Figure 33). These results were in 
agreement with literature where the amphipathic region peptides displayed the highest 
propensity to form α-helices and were assigned to be the first ones to initiate structural folding 
in the presence of the vesicle’s membrane 78. The NAC region for plots B) and C) displayed very 
little decrease in deuterium uptake across all 6 time points (Figure 33). Compared to the aliphatic 
region of αSN, little structural refolding happened in the NAC region. These results rejected the 
idea of αSN obtaining the extended-helix or the broken-helix states upon the first few seconds of 
interactions with the DMPC-POPS nanodiscs. However, as previously mentioned, the NAC region 
only follows the amphipathic part in a coil/helix transition (this was more distinct in the longer 
time points in Figure 32). Therefore, it takes time to fold into a structured helix which could not 
be captured in millisecond time-scale of the kinetic experiment 78. The NAC region in plot A) 
showed more of a decrease in deuterium uptake than the other two plots, suggesting some 
structural folding due to some transient interaction with the nanodisc’s membrane. 
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Figure 33. Summed deuterium uptake difference plot between A) αSN - 6 nm DMPC nanodisc 
complex and αSN alone, B) and C)  αSN - 6 nm DMPC-POPS nanodisc complex and αSN alone. 
Blue color represents decrease in D2O uptake, red increase,  and grey - no significant change or 
no HDX data was obtained. 
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     Such differences in the HDX profiles between all three plots in Figure 33 prevent from 
achieving any firm conclusions on the structural dynamics of the NAC region in the presence of 
the DMPC or DMPC-POPS nanodiscs. More replicates of the kinetic studies are needed in future.  
     The C-terminus peptides (amino acids 99-126) gave very infrequent deuterium uptake profiles 
as well. Overall, QLGKNEEGAPQE 99-110 and LGKNEEGAPQ 100-109 displayed decreases in 
deuterium uptake when exposed to the lipid bilayer of the nanodisc. EDMPVDPDNEAYE 114-126, 
in its turn, showed either decrease (plot A), increase (plot B), or no significant difference (plot C) 
in deuterium uptake. The HDX profiles for C-terminus peptides did not indicate any consistent 
structural behaviour during interaction with the lipid bilayer of the nanodiscs. However, it could 
be explained by the disordered character of the C-terminus which may form ensemble of 
different structural conformations resulting in different HDX results. The unexpected decreases 
in deuterium uptake mostly observed for LGKNEEGAPQ 100-109 were proposed to be result of 
assisting of this region in reducing αSN’s disordered character towards a more folded species 
through the interaction with either regions of αSN or nanodiscs.  
      In conclusion, the kinetic studies have shown that αSN had exhibited rather transient 
interactions with the lipid membrane of the DMPC or DMPC-POPS nanodiscs. This deduction was 
supported by the recent NMR research by Viennet et al. which indicated no binding of αSN to the 
DMPC nanodisc or nanodiscs with less than 25% of negatively charged lipids 173. However, 
compared to NMR, TRESI-HDX-MS (as a more sensitive technique to the structural perturbations 
in the amide backbone) was able to show that the presence of the nanodiscs resulted in the 
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transition of αSN towards a more conformationally-rigid structure. In addition, the overall 
decrease in deuterium uptake for the amphipathic region peptides compared to inconsistent HDX 
profiles for the other two regions of αSN could be the first indication of the partial-helical 
intermediate that was described by Dikiy and Eliezer in their model for the structural behaviour 
of this protein when interacting with synaptic vesicles (section 1.3.3.2. and Figure 14) 141. 
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Chapter 4: Conclusion and Future Work 
4.1. Conclusion 
     The current study was successful in using TRESI-HDX-MS for the structural analysis of αSN in 
the presence of the nanodisc’s phospholipid bilayer. Probing the dynamics of non- to weakly 
structured regions of αSN on the millisecond to seconds time scale has helped to elucidate the 
key regions involved in the structural changes during the protein-lipid interaction. Both 
equilibrium and kinetic studies have indicated the transient interaction of lipid-binding domain 
of αSN with the DMPC or DMPC-POPS nanodiscs, with the greatest transition to more structurally 
folded state in the amphipathic region of αSN. Nanodisc technology provided “nature-like” 
environment for αSN and gave more insights in possible  in vivo conformational behavior of this 
protein, for example, the kinetic studies data could support the evidence for the formation of the 
partial-helical intermediate that was described by Dikiy and Eliezer. 
     The main research objective of this Master’s thesis was to elucidate conformational dynamics 
of αSN’s folding pathway into an extended-helix or broken-helix state. Understanding of the key 
transitional intermediates in this pathway may facilitate investigation for a drug that can stabilize 
the native folded state of αSN and prevent aggregation of this protein in neuronal cytosol.   
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4.2. Future Work 
     To address inconsistency issues in sections 3.5 and 3.6, as well as, complement the results in 
this research the set of future experiments was proposed. The main goals of the future 
experimental workflow are depicted in Figure 24. 
 
Figure 34. Diagram featuring the plan for future work experiments. The first step includes the 
implementation of microfluidic chip with zirconium oxide beads in TRESI-HDX-MS workflow. This 
will be followed by the testing of two different protein samples – αSN and phosphorylated αSN 
against three different nanodiscs (DMPC, DMPC:POPG, and POPG) with different lipid-to-protein 
ratios. Lat step involves testing mutated versions of αSN against DMPC, DMPC:POPG, and POPG 
nanodiscs with different lipid-to-protein ratios.   
 
     The first proposed improvement is the implementation of the second microfluidic chip filled 
with zirconium oxide beads right before ESI capillary in the TRESI set up. Zirconium oxide will help 
to clean up the sample from detergents and lipids which substantially supress peptide signal in 
MS. This will allow for a greater peptide coverage of the amphipathic region of αSN. Once TRESI 
system is successfully upgraded with zirconium oxide chip, TRESI-HDX-MS would be run on αSN 
with DMPC nanodiscs to obtain missing replicates. More negatively charged DMPC-POPG and 
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POPG nanodiscs will also be tested with αSN as actual binding with these two types of lipid bilayer 
nanodiscs was proved by Viennet et al. in 2018 173. Different lipid-to-protein (L:P) ratios were also 
proposed to be tried out due to the reported aggregation propensities of αSN in response to the 
different L:P ratios 172. Similar to αSN TRESI-HDX-MS experiments are planned for the 
phosphorylated αSN. Phosphorylated αSN at Ser129 has been reported to enhance αSN’s toxicity 
both in vivo and in vitro, possibly by increasing the formation of αSN’s aggregates 174. In a long-
term future, TRESI-HDX-MS experiments with the three different nanodisc bilayers could be 
extended to the three main mutations in αSN (A30P, E46K and A53T) which were shown to exhibit 
an impact on the binding capacities to the vesicle’s membrane in vitro 141. 
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